| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| 3E00X05 | Introduction of Other Antineoplastic into Skin and Mucous Membranes, External Approach |
| 3E00X0M | Introduction of Antineoplastic, Monoclonal Antibody, into Skin and Mucous Membranes, External Approach |
| 3E00X28 | Introduction of Oxazolidinones into Skin and Mucous Membranes, External Approach |
| 3E00X29 | Introduction of Other Anti-infective into Skin and Mucous Membranes, External Approach |
| 3E00X3Z | Introduction of Anti-inflammatory into Skin and Mucous Membranes, External Approach |
| 3E00X4Z | Introduction of Serum, Toxoid and Vaccine into Skin and Mucous Membranes, External Approach |
| 3E00XBZ | Introduction of Anesthetic Agent into Skin and Mucous Membranes, External Approach |
| 3E00XGC | Introduction of Other Therapeutic Substance into Skin and Mucous Membranes, External Approach |
| 3E00XKZ | Introduction of Other Diagnostic Substance into Skin and Mucous Membranes, External Approach |
| 3E00XMZ | Introduction of Pigment into Skin and Mucous Membranes, External Approach |
| 3E00XNZ | Introduction of Analgesics, Hypnotics, Sedatives into Skin and Mucous Membranes, External Approach |
| 3E00XTZ | Introduction of Destructive Agent into Skin and Mucous Membranes, External Approach |
| 3E0102A | Introduction of Anti-Infective Envelope into Subcutaneous Tissue, Open Approach |
| 3E01305 | Introduction of Other Antineoplastic into Subcutaneous Tissue, Percutaneous Approach |
| 3E0130M | Introduction of Antineoplastic, Monoclonal Antibody, into Subcutaneous Tissue, Percutaneous Approach |
| 3E01328 | Introduction of Oxazolidinones into Subcutaneous Tissue, Percutaneous Approach |
| 3E01329 | Introduction of Other Anti-infective into Subcutaneous Tissue, Percutaneous Approach |
| 3E0132A | Introduction of Anti-Infective Envelope into Subcutaneous Tissue, Percutaneous Approach |
| 3E0133Z | Introduction of Anti-inflammatory into Subcutaneous Tissue, Percutaneous Approach |
| 3E01340 | Introduction of Influenza Vaccine into Subcutaneous Tissue, Percutaneous Approach |
| 3E0134Z | Introduction of Serum, Toxoid and Vaccine into Subcutaneous Tissue, Percutaneous Approach |
| 3E0136Z | Introduction of Nutritional Substance into Subcutaneous Tissue, Percutaneous Approach |
| 3E0137Z | Introduction of Electrolytic and Water Balance Substance into Subcutaneous Tissue, Percutaneous Approach |
| 3E013BZ | Introduction of Anesthetic Agent into Subcutaneous Tissue, Percutaneous Approach |
| 3E013GC | Introduction of Other Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach |
| 3E013HZ | Introduction of Radioactive Substance into Subcutaneous Tissue, Percutaneous Approach |
| 3E013KZ | Introduction of Other Diagnostic Substance into Subcutaneous Tissue, Percutaneous Approach |
| 3E013NZ | Introduction of Analgesics, Hypnotics, Sedatives into Subcutaneous Tissue, Percutaneous Approach |
| 3E013TZ | Introduction of Destructive Agent into Subcutaneous Tissue, Percutaneous Approach |
| 3E013VG | Introduction of Insulin into Subcutaneous Tissue, Percutaneous Approach |
| 3E013VJ | Introduction of Other Hormone into Subcutaneous Tissue, Percutaneous Approach |
| 3E02305 | Introduction of Other Antineoplastic into Muscle, Percutaneous Approach |
| 3E0230M | Introduction of Antineoplastic, Monoclonal Antibody, into Muscle, Percutaneous Approach |
| 3E02328 | Introduction of Oxazolidinones into Muscle, Percutaneous Approach |
| 3E02329 | Introduction of Other Anti-infective into Muscle, Percutaneous Approach |
| 3E0233Z | Introduction of Anti-inflammatory into Muscle, Percutaneous Approach |
| 3E02340 | Introduction of Influenza Vaccine into Muscle, Percutaneous Approach |
| 3E0234Z | Introduction of Serum, Toxoid and Vaccine into Muscle, Percutaneous Approach |
| 3E0236Z | Introduction of Nutritional Substance into Muscle, Percutaneous Approach |
| 3E0237Z | Introduction of Electrolytic and Water Balance Substance into Muscle, Percutaneous Approach |
| 3E023BZ | Introduction of Anesthetic Agent into Muscle, Percutaneous Approach |
| 3E023GC | Introduction of Other Therapeutic Substance into Muscle, Percutaneous Approach |
| 3E023HZ | Introduction of Radioactive Substance into Muscle, Percutaneous Approach |
| 3E023KZ | Introduction of Other Diagnostic Substance into Muscle, Percutaneous Approach |
| 3E023NZ | Introduction of Analgesics, Hypnotics, Sedatives into Muscle, Percutaneous Approach |
| 3E023TZ | Introduction of Destructive Agent into Muscle, Percutaneous Approach |
| 3E03002 | Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach |
| 3E03003 | Introduction of Low-dose Interleukin-2 into Peripheral Vein, Open Approach |
| 3E03005 | Introduction of Other Antineoplastic into Peripheral Vein, Open Approach |
| 3E0300M | Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Open Approach |
| 3E0300P | Introduction of Clofarabine into Peripheral Vein, Open Approach |
| 3E03016 | Introduction of Recombinant Human-activated Protein C into Peripheral Vein, Open |
| 3E03017 | Introduction of Other Thrombolytic into Peripheral Vein, Open Approach |
| 3E03028 | Introduction of Oxazolidinones into Peripheral Vein, Open Approach |
| 3E03029 | Introduction of Other Anti-infective into Peripheral Vein, Open Approach |
| 3E0303Z | Introduction of Anti-inflammatory into Peripheral Vein, Open Approach |
| 3E0304Z | Introduction of Serum, Toxoid and Vaccine into Peripheral Vein, Open Approach |
| 3E0306Z | Introduction of Nutritional Substance into Peripheral Vein, Open Approach |
| 3E0307Z | Introduction of Electrolytic and Water Balance Substance into Peripheral Vein, Open Approach |
| 3E030FZ | Introduction of Intracirculatory Anesthetic into Peripheral Vein, Open Approach |
| 3E030GC | Introduction of Other Therapeutic Substance into Peripheral Vein, Open Approach |
| 3E030GN | Introduction of Blood Brain Barrier Disruption Substance into Peripheral Vein, Open Approach |
| 3E030HZ | Introduction of Radioactive Substance into Peripheral Vein, Open Approach |
| 3E030KZ | Introduction of Other Diagnostic Substance into Peripheral Vein, Open Approach |
| 3E030NZ | Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Vein, Open Approach |
| 3E030PZ | Introduction of Platelet Inhibitor into Peripheral Vein, Open Approach |
| 3E030RZ | Introduction of Antiarrhythmic into Peripheral Vein, Open Approach |
| 3E030TZ | Introduction of Destructive Agent into Peripheral Vein, Open Approach |
| 3E030U0 | Introduction of Autologous Pancreatic Islet Cells into Peripheral Vein, Open Approach |
| 3E030U1 | Introduction of Nonautologous Pancreatic Islet Cells into Peripheral Vein, Open Approach |
| 3E030VG | Introduction of Insulin into Peripheral Vein, Open Approach |
| 3E030VH | Introduction of Human B-type Natriuretic Peptide into Peripheral Vein, Open Approach |
| 3E030VJ | Introduction of Other Hormone into Peripheral Vein, Open Approach |
| 3E030WK | Introduction of Immunostimulator into Peripheral Vein, Open |
| 3E030WL | Introduction of Immunosuppressive into Peripheral Vein, Open |
| 3E030XZ | Introduction of Vasopressor into Peripheral Vein, Open Approach |
| 3E03302 | Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach |
| 3E03303 | Introduction of Low-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach |
| 3E03305 | Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach |
| 3E0330M | Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Percutaneous Approach |
| 3E0330P | Introduction of Clofarabine into Peripheral Vein, Percutaneous Approach |
| 3E03316 | Introduction of Recombinant Human-activated Protein C into Peripheral Vein, Percutaneous |
| 3E03317 | Introduction of Other Thrombolytic into Peripheral Vein, Percutaneous Approach |
| 3E03328 | Introduction of Oxazolidinones into Peripheral Vein, Percutaneous Approach |
| 3E03329 | Introduction of Other Anti-infective into Peripheral Vein, Percutaneous Approach |
| 3E0333Z | Introduction of Anti-inflammatory into Peripheral Vein, Percutaneous Approach |
| 3E0334Z | Introduction of Serum, Toxoid and Vaccine into Peripheral Vein, Percutaneous Approach |
| 3E0336Z | Introduction of Nutritional Substance into Peripheral Vein, Percutaneous Approach |
| 3E0337Z | Introduction of Electrolytic and Water Balance Substance into Peripheral Vein, Percutaneous Approach |
| 3E033FZ | Introduction of Intracirculatory Anesthetic into Peripheral Vein, Percutaneous Approach |
| 3E033GC | Introduction of Other Therapeutic Substance into Peripheral Vein, Percutaneous Approach |
| 3E033GN | Introduction of Blood Brain Barrier Disruption Substance into Peripheral Vein, Percutaneous Approach |
| 3E033GQ | Introduction of Glucarpidase into Peripheral Vein, Percutaneous Approach |
| 3E033GR | Introduction of Other Therapeutic Monoclonal Antibody into Peripheral Vein, Percutaneous Approach |
| 3E033HZ | Introduction of Radioactive Substance into Peripheral Vein, Percutaneous Approach |
| 3E033KZ | Introduction of Other Diagnostic Substance into Peripheral Vein, Percutaneous Approach |
| 3E033NZ | Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Vein, Percutaneous Approach |
| 3E033PZ | Introduction of Platelet Inhibitor into Peripheral Vein, Percutaneous Approach |
| 3E033RZ | Introduction of Antiarrhythmic into Peripheral Vein, Percutaneous Approach |
| 3E033TZ | Introduction of Destructive Agent into Peripheral Vein, Percutaneous Approach |
| 3E033U0 | Introduction of Autologous Pancreatic Islet Cells into Peripheral Vein, Percutaneous Approach |
| 3E033U1 | Introduction of Nonautologous Pancreatic Islet Cells into Peripheral Vein, Percutaneous Approach |
| 3E033VG | Introduction of Insulin into Peripheral Vein, Percutaneous Approach |
| 3E033VH | Introduction of Human B-type Natriuretic Peptide into Peripheral Vein, Percutaneous Approach |
| 3E033VJ | Introduction of Other Hormone into Peripheral Vein, Percutaneous Approach |
| 3E033WK | Introduction of Immunostimulator into Peripheral Vein, Percutaneous |
| 3E033WL | Introduction of Immunosuppressive into Peripheral Vein, Percutaneous |
| 3E033XZ | Introduction of Vasopressor into Peripheral Vein, Percutaneous Approach |
| 3E04002 | Introduction of High-dose Interleukin-2 into Central Vein, Open Approach |
| 3E04003 | Introduction of Low-dose Interleukin-2 into Central Vein, Open Approach |
| 3E04005 | Introduction of Other Antineoplastic into Central Vein, Open Approach |
| 3E0400M | Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Open Approach |
| 3E0400P | Introduction of Clofarabine into Central Vein, Open Approach |
| 3E04016 | Introduction of Recombinant Human-activated Protein C into Central Vein, Open |
| 3E04017 | Introduction of Other Thrombolytic into Central Vein, Open Approach |
| 3E04028 | Introduction of Oxazolidinones into Central Vein, Open Approach |
| 3E04029 | Introduction of Other Anti-infective into Central Vein, Open Approach |
| 3E0403Z | Introduction of Anti-inflammatory into Central Vein, Open Approach |
| 3E0404Z | Introduction of Serum, Toxoid and Vaccine into Central Vein, Open Approach |
| 3E0406Z | Introduction of Nutritional Substance into Central Vein, Open Approach |
| 3E0407Z | Introduction of Electrolytic and Water Balance Substance into Central Vein, Open Approach |
| 3E040FZ | Introduction of Intracirculatory Anesthetic into Central Vein, Open Approach |
| 3E040GC | Introduction of Other Therapeutic Substance into Central Vein, Open Approach |
| 3E040GN | Introduction of Blood Brain Barrier Disruption Substance into Central Vein, Open Approach |
| 3E040HZ | Introduction of Radioactive Substance into Central Vein, Open Approach |
| 3E040KZ | Introduction of Other Diagnostic Substance into Central Vein, Open Approach |
| 3E040NZ | Introduction of Analgesics, Hypnotics, Sedatives into Central Vein, Open Approach |
| 3E040PZ | Introduction of Platelet Inhibitor into Central Vein, Open Approach |
| 3E040RZ | Introduction of Antiarrhythmic into Central Vein, Open Approach |
| 3E040TZ | Introduction of Destructive Agent into Central Vein, Open Approach |
| 3E040VG | Introduction of Insulin into Central Vein, Open Approach |
| 3E040VH | Introduction of Human B-type Natriuretic Peptide into Central Vein, Open Approach |
| 3E040VJ | Introduction of Other Hormone into Central Vein, Open Approach |
| 3E040WK | Introduction of Immunostimulator into Central Vein, Open |
| 3E040WL | Introduction of Immunosuppressive into Central Vein, Open |
| 3E040XZ | Introduction of Vasopressor into Central Vein, Open Approach |
| 3E04302 | Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach |
| 3E04303 | Introduction of Low-dose Interleukin-2 into Central Vein, Percutaneous Approach |
| 3E04305 | Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach |
| 3E0430M | Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Percutaneous Approach |
| 3E0430P | Introduction of Clofarabine into Central Vein, Percutaneous Approach |
| 3E04316 | Introduction of Recombinant Human-activated Protein C into Central Vein, Percutaneous |
| 3E04317 | Introduction of Other Thrombolytic into Central Vein, Percutaneous Approach |
| 3E04328 | Introduction of Oxazolidinones into Central Vein, Percutaneous Approach |
| 3E04329 | Introduction of Other Anti-infective into Central Vein, Percutaneous Approach |
| 3E0433Z | Introduction of Anti-inflammatory into Central Vein, Percutaneous Approach |
| 3E0434Z | Introduction of Serum, Toxoid and Vaccine into Central Vein, Percutaneous Approach |
| 3E0436Z | Introduction of Nutritional Substance into Central Vein, Percutaneous Approach |
| 3E0437Z | Introduction of Electrolytic and Water Balance Substance into Central Vein, Percutaneous Approach |
| 3E043FZ | Introduction of Intracirculatory Anesthetic into Central Vein, Percutaneous Approach |
| 3E043GC | Introduction of Other Therapeutic Substance into Central Vein, Percutaneous Approach |
| 3E043GN | Introduction of Blood Brain Barrier Disruption Substance into Central Vein, Percutaneous Approach |
| 3E043GQ | Introduction of Glucarpidase into Central Vein, Percutaneous Approach |
| 3E043GR | Introduction of Other Therapeutic Monoclonal Antibody into Central Vein, Percutaneous Approach |
| 3E043HZ | Introduction of Radioactive Substance into Central Vein, Percutaneous Approach |
| 3E043KZ | Introduction of Other Diagnostic Substance into Central Vein, Percutaneous Approach |
| 3E043NZ | Introduction of Analgesics, Hypnotics, Sedatives into Central Vein, Percutaneous Approach |
| 3E043PZ | Introduction of Platelet Inhibitor into Central Vein, Percutaneous Approach |
| 3E043RZ | Introduction of Antiarrhythmic into Central Vein, Percutaneous Approach |
| 3E043TZ | Introduction of Destructive Agent into Central Vein, Percutaneous Approach |
| 3E043VG | Introduction of Insulin into Central Vein, Percutaneous Approach |
| 3E043VH | Introduction of Human B-type Natriuretic Peptide into Central Vein, Percutaneous Approach |
| 3E043VJ | Introduction of Other Hormone into Central Vein, Percutaneous Approach |
| 3E043WK | Introduction of Immunostimulator into Central Vein, Percutaneous |
| 3E043WL | Introduction of Immunosuppressive into Central Vein, Percutaneous |
| 3E043XZ | Introduction of Vasopressor into Central Vein, Percutaneous Approach |
| 3E05002 | Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach |
| 3E05003 | Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach |
| 3E05005 | Introduction of Other Antineoplastic into Peripheral Artery, Open Approach |
| 3E0500M | Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Open Approach |
| 3E0500P | Introduction of Clofarabine into Peripheral Artery, Open Approach |
| 3E05016 | Introduction of Recombinant Human-activated Protein C into Peripheral Artery, Open |
| 3E05017 | Introduction of Other Thrombolytic into Peripheral Artery, Open Approach |
| 3E05028 | Introduction of Oxazolidinones into Peripheral Artery, Open Approach |
| 3E05029 | Introduction of Other Anti-infective into Peripheral Artery, Open Approach |
| 3E0503Z | Introduction of Anti-inflammatory into Peripheral Artery, Open Approach |
| 3E0504Z | Introduction of Serum, Toxoid and Vaccine into Peripheral Artery, Open Approach |
| 3E0506Z | Introduction of Nutritional Substance into Peripheral Artery, Open Approach |
| 3E0507Z | Introduction of Electrolytic and Water Balance Substance into Peripheral Artery, Open Approach |
| 3E050FZ | Introduction of Intracirculatory Anesthetic into Peripheral Artery, Open Approach |
| 3E050GC | Introduction of Other Therapeutic Substance into Peripheral Artery, Open Approach |
| 3E050GN | Introduction of Blood Brain Barrier Disruption Substance into Peripheral Artery, Open Approach |
| 3E050HZ | Introduction of Radioactive Substance into Peripheral Artery, Open Approach |
| 3E050KZ | Introduction of Other Diagnostic Substance into Peripheral Artery, Open Approach |
| 3E050NZ | Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Artery, Open Approach |
| 3E050PZ | Introduction of Platelet Inhibitor into Peripheral Artery, Open Approach |
| 3E050RZ | Introduction of Antiarrhythmic into Peripheral Artery, Open Approach |
| 3E050TZ | Introduction of Destructive Agent into Peripheral Artery, Open Approach |
| 3E050VG | Introduction of Insulin into Peripheral Artery, Open Approach |
| 3E050VH | Introduction of Human B-type Natriuretic Peptide into Peripheral Artery, Open Approach |
| 3E050VJ | Introduction of Other Hormone into Peripheral Artery, Open Approach |
| 3E050WK | Introduction of Immunostimulator into Peripheral Artery, Open |
| 3E050WL | Introduction of Immunosuppressive into Peripheral Artery, Open |
| 3E050XZ | Introduction of Vasopressor into Peripheral Artery, Open Approach |
| 3E05302 | Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach |
| 3E05303 | Introduction of Low-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach |
| 3E05305 | Introduction of Other Antineoplastic into Peripheral Artery, Percutaneous Approach |
| 3E0530M | Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Percutaneous Approach |
| 3E0530P | Introduction of Clofarabine into Peripheral Artery, Percutaneous Approach |
| 3E05316 | Introduction of Recombinant Human-activated Protein C into Peripheral Artery, Percutaneous |
| 3E05317 | Introduction of Other Thrombolytic into Peripheral Artery, Percutaneous Approach |
| 3E05328 | Introduction of Oxazolidinones into Peripheral Artery, Percutaneous Approach |
| 3E05329 | Introduction of Other Anti-infective into Peripheral Artery, Percutaneous Approach |
| 3E0533Z | Introduction of Anti-inflammatory into Peripheral Artery, Percutaneous Approach |
| 3E0534Z | Introduction of Serum, Toxoid and Vaccine into Peripheral Artery, Percutaneous Approach |
| 3E0536Z | Introduction of Nutritional Substance into Peripheral Artery, Percutaneous Approach |
| 3E0537Z | Introduction of Electrolytic and Water Balance Substance into Peripheral Artery, Percutaneous Approach |
| 3E053FZ | Introduction of Intracirculatory Anesthetic into Peripheral Artery, Percutaneous Approach |
| 3E053GC | Introduction of Other Therapeutic Substance into Peripheral Artery, Percutaneous Approach |
| 3E053GN | Introduction of Blood Brain Barrier Disruption Substance into Peripheral Artery, Percutaneous Approach |
| 3E053HZ | Introduction of Radioactive Substance into Peripheral Artery, Percutaneous Approach |
| 3E053KZ | Introduction of Other Diagnostic Substance into Peripheral Artery, Percutaneous Approach |
| 3E053NZ | Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Artery, Percutaneous Approach |
| 3E053PZ | Introduction of Platelet Inhibitor into Peripheral Artery, Percutaneous Approach |
| 3E053RZ | Introduction of Antiarrhythmic into Peripheral Artery, Percutaneous Approach |
| 3E053TZ | Introduction of Destructive Agent into Peripheral Artery, Percutaneous Approach |
| 3E053VG | Introduction of Insulin into Peripheral Artery, Percutaneous Approach |
| 3E053VH | Introduction of Human B-type Natriuretic Peptide into Peripheral Artery, Percutaneous Approach |
| 3E053VJ | Introduction of Other Hormone into Peripheral Artery, Percutaneous Approach |
| 3E053WK | Introduction of Immunostimulator into Peripheral Artery, Percutaneous |
| 3E053WL | Introduction of Immunosuppressive into Peripheral Artery, Percutaneous |
| 3E053XZ | Introduction of Vasopressor into Peripheral Artery, Percutaneous Approach |
| 3E06002 | Introduction of High-dose Interleukin-2 into Central Artery, Open Approach |
| 3E06003 | Introduction of Low-dose Interleukin-2 into Central Artery, Open Approach |
| 3E06005 | Introduction of Other Antineoplastic into Central Artery, Open Approach |
| 3E0600M | Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Open Approach |
| 3E0600P | Introduction of Clofarabine into Central Artery, Open Approach |
| 3E06016 | Introduction of Recombinant Human-activated Protein C into Central Artery, Open |
| 3E06017 | Introduction of Other Thrombolytic into Central Artery, Open Approach |
| 3E06028 | Introduction of Oxazolidinones into Central Artery, Open Approach |
| 3E06029 | Introduction of Other Anti-infective into Central Artery, Open Approach |
| 3E0603Z | Introduction of Anti-inflammatory into Central Artery, Open Approach |
| 3E0604Z | Introduction of Serum, Toxoid and Vaccine into Central Artery, Open Approach |
| 3E0606Z | Introduction of Nutritional Substance into Central Artery, Open Approach |
| 3E0607Z | Introduction of Electrolytic and Water Balance Substance into Central Artery, Open Approach |
| 3E060FZ | Introduction of Intracirculatory Anesthetic into Central Artery, Open Approach |
| 3E060GC | Introduction of Other Therapeutic Substance into Central Artery, Open Approach |
| 3E060GN | Introduction of Blood Brain Barrier Disruption Substance into Central Artery, Open Approach |
| 3E060HZ | Introduction of Radioactive Substance into Central Artery, Open Approach |
| 3E060KZ | Introduction of Other Diagnostic Substance into Central Artery, Open Approach |
| 3E060NZ | Introduction of Analgesics, Hypnotics, Sedatives into Central Artery, Open Approach |
| 3E060PZ | Introduction of Platelet Inhibitor into Central Artery, Open Approach |
| 3E060RZ | Introduction of Antiarrhythmic into Central Artery, Open Approach |
| 3E060TZ | Introduction of Destructive Agent into Central Artery, Open Approach |
| 3E060VG | Introduction of Insulin into Central Artery, Open Approach |
| 3E060VH | Introduction of Human B-type Natriuretic Peptide into Central Artery, Open Approach |
| 3E060VJ | Introduction of Other Hormone into Central Artery, Open Approach |
| 3E060WK | Introduction of Immunostimulator into Central Artery, Open |
| 3E060WL | Introduction of Immunosuppressive into Central Artery, Open |
| 3E060XZ | Introduction of Vasopressor into Central Artery, Open Approach |
| 3E06302 | Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach |
| 3E06303 | Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach |
| 3E06305 | Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach |
| 3E0630M | Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Percutaneous Approach |
| 3E0630P | Introduction of Clofarabine into Central Artery, Percutaneous Approach |
| 3E06316 | Introduction of Recombinant Human-activated Protein C into Central Artery, Percutaneous |
| 3E06317 | Introduction of Other Thrombolytic into Central Artery, Percutaneous Approach |
| 3E06328 | Introduction of Oxazolidinones into Central Artery, Percutaneous Approach |
| 3E06329 | Introduction of Other Anti-infective into Central Artery, Percutaneous Approach |
| 3E0633Z | Introduction of Anti-inflammatory into Central Artery, Percutaneous Approach |
| 3E0634Z | Introduction of Serum, Toxoid and Vaccine into Central Artery, Percutaneous Approach |
| 3E0636Z | Introduction of Nutritional Substance into Central Artery, Percutaneous Approach |
| 3E0637Z | Introduction of Electrolytic and Water Balance Substance into Central Artery, Percutaneous Approach |
| 3E063FZ | Introduction of Intracirculatory Anesthetic into Central Artery, Percutaneous Approach |
| 3E063GC | Introduction of Other Therapeutic Substance into Central Artery, Percutaneous Approach |
| 3E063GN | Introduction of Blood Brain Barrier Disruption Substance into Central Artery, Percutaneous Approach |
| 3E063HZ | Introduction of Radioactive Substance into Central Artery, Percutaneous Approach |
| 3E063KZ | Introduction of Other Diagnostic Substance into Central Artery, Percutaneous Approach |
| 3E063NZ | Introduction of Analgesics, Hypnotics, Sedatives into Central Artery, Percutaneous Approach |
| 3E063PZ | Introduction of Platelet Inhibitor into Central Artery, Percutaneous Approach |
| 3E063RZ | Introduction of Antiarrhythmic into Central Artery, Percutaneous Approach |
| 3E063TZ | Introduction of Destructive Agent into Central Artery, Percutaneous Approach |
| 3E063VG | Introduction of Insulin into Central Artery, Percutaneous Approach |
| 3E063VH | Introduction of Human B-type Natriuretic Peptide into Central Artery, Percutaneous Approach |
| 3E063VJ | Introduction of Other Hormone into Central Artery, Percutaneous Approach |
| 3E063WK | Introduction of Immunostimulator into Central Artery, Percutaneous |
| 3E063WL | Introduction of Immunosuppressive into Central Artery, Percutaneous |
| 3E063XZ | Introduction of Vasopressor into Central Artery, Percutaneous Approach |
| 3E07016 | Introduction of Recombinant Human-activated Protein C into Coronary Artery, Open |
| 3E07017 | Introduction of Other Thrombolytic into Coronary Artery, Open Approach |
| 3E070GC | Introduction of Other Therapeutic Substance into Coronary Artery, Open Approach |
| 3E070KZ | Introduction of Other Diagnostic Substance into Coronary Artery, Open Approach |
| 3E070PZ | Introduction of Platelet Inhibitor into Coronary Artery, Open Approach |
| 3E07316 | Introduction of Recombinant Human-activated Protein C into Coronary Artery, Percutaneous |
| 3E07317 | Introduction of Other Thrombolytic into Coronary Artery, Percutaneous Approach |
| 3E073GC | Introduction of Other Therapeutic Substance into Coronary Artery, Percutaneous Approach |
| 3E073KZ | Introduction of Other Diagnostic Substance into Coronary Artery, Percutaneous Approach |
| 3E073PZ | Introduction of Platelet Inhibitor into Coronary Artery, Percutaneous Approach |
| 3E074GC | Introduction of Other Therapeutic Substance into Coronary Artery, Percutaneous Endoscopic Approach |
| 3E08016 | Introduction of Recombinant Human-activated Protein C into Heart, Open |
| 3E08017 | Introduction of Other Thrombolytic into Heart, Open Approach |
| 3E080GC | Introduction of Other Therapeutic Substance into Heart, Open Approach |
| 3E080KZ | Introduction of Other Diagnostic Substance into Heart, Open Approach |
| 3E080PZ | Introduction of Platelet Inhibitor into Heart, Open Approach |
| 3E08316 | Introduction of Recombinant Human-activated Protein C into Heart, Percutaneous |
| 3E08317 | Introduction of Other Thrombolytic into Heart, Percutaneous Approach |
| 3E083GC | Introduction of Other Therapeutic Substance into Heart, Percutaneous Approach |
| 3E083KZ | Introduction of Other Diagnostic Substance into Heart, Percutaneous Approach |
| 3E083PZ | Introduction of Platelet Inhibitor into Heart, Percutaneous Approach |
| 3E084GC | Introduction of Other Therapeutic Substance into Heart, Percutaneous Endoscopic Approach |
| 3E09305 | Introduction of Other Antineoplastic into Nose, Percutaneous Approach |
| 3E0930M | Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Percutaneous Approach |
| 3E09328 | Introduction of Oxazolidinones into Nose, Percutaneous Approach |
| 3E09329 | Introduction of Other Anti-infective into Nose, Percutaneous Approach |
| 3E0933Z | Introduction of Anti-inflammatory into Nose, Percutaneous Approach |
| 3E0934Z | Introduction of Serum, Toxoid and Vaccine into Nose, Percutaneous Approach |
| 3E093BZ | Introduction of Anesthetic Agent into Nose, Percutaneous Approach |
| 3E093GC | Introduction of Other Therapeutic Substance into Nose, Percutaneous Approach |
| 3E093HZ | Introduction of Radioactive Substance into Nose, Percutaneous Approach |
| 3E093KZ | Introduction of Other Diagnostic Substance into Nose, Percutaneous Approach |
| 3E093NZ | Introduction of Analgesics, Hypnotics, Sedatives into Nose, Percutaneous Approach |
| 3E093TZ | Introduction of Destructive Agent into Nose, Percutaneous Approach |
| 3E09705 | Introduction of Other Antineoplastic into Nose, Via Natural or Artificial Opening |
| 3E0970M | Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Via Natural or Artificial Opening |
| 3E09728 | Introduction of Oxazolidinones into Nose, Via Natural or Artificial Opening |
| 3E09729 | Introduction of Other Anti-infective into Nose, Via Natural or Artificial Opening |
| 3E0973Z | Introduction of Anti-inflammatory into Nose, Via Natural or Artificial Opening |
| 3E0974Z | Introduction of Serum, Toxoid and Vaccine into Nose, Via Natural or Artificial Opening |
| 3E097BZ | Introduction of Anesthetic Agent into Nose, Via Natural or Artificial Opening |
| 3E097GC | Introduction of Other Therapeutic Substance into Nose, Via Natural or Artificial Opening |
| 3E097HZ | Introduction of Radioactive Substance into Nose, Via Natural or Artificial Opening |
| 3E097KZ | Introduction of Other Diagnostic Substance into Nose, Via Natural or Artificial Opening |
| 3E097NZ | Introduction of Analgesics, Hypnotics, Sedatives into Nose, Via Natural or Artificial Opening |
| 3E097TZ | Introduction of Destructive Agent into Nose, Via Natural or Artificial Opening |
| 3E09X05 | Introduction of Other Antineoplastic into Nose, External Approach |
| 3E09X0M | Introduction of Antineoplastic, Monoclonal Antibody, into Nose, External Approach |
| 3E09X28 | Introduction of Oxazolidinones into Nose, External Approach |
| 3E09X29 | Introduction of Other Anti-infective into Nose, External Approach |
| 3E09X3Z | Introduction of Anti-inflammatory into Nose, External Approach |
| 3E09X4Z | Introduction of Serum, Toxoid and Vaccine into Nose, External Approach |
| 3E09XBZ | Introduction of Anesthetic Agent into Nose, External Approach |
| 3E09XGC | Introduction of Other Therapeutic Substance into Nose, External Approach |
| 3E09XHZ | Introduction of Radioactive Substance into Nose, External Approach |
| 3E09XKZ | Introduction of Other Diagnostic Substance into Nose, External Approach |
| 3E09XNZ | Introduction of Analgesics, Hypnotics, Sedatives into Nose, External Approach |
| 3E09XTZ | Introduction of Destructive Agent into Nose, External Approach |
| 3E0A305 | Introduction of Other Antineoplastic into Bone Marrow, Percutaneous Approach |
| 3E0A30M | Introduction of Antineoplastic, Monoclonal Antibody, into Bone Marrow, Percutaneous Approach |
| 3E0A3GC | Introduction of Other Therapeutic Substance into Bone Marrow, Percutaneous Approach |
| 3E0B304 | Introduction of Liquid Brachytherapy Radioisotope into Ear, Percutaneous Approach |
| 3E0B305 | Introduction of Other Antineoplastic into Ear, Percutaneous Approach |
| 3E0B30M | Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Percutaneous Approach |
| 3E0B328 | Introduction of Oxazolidinones into Ear, Percutaneous Approach |
| 3E0B329 | Introduction of Other Anti-infective into Ear, Percutaneous Approach |
| 3E0B33Z | Introduction of Anti-inflammatory into Ear, Percutaneous Approach |
| 3E0B3BZ | Introduction of Anesthetic Agent into Ear, Percutaneous Approach |
| 3E0B3GC | Introduction of Other Therapeutic Substance into Ear, Percutaneous Approach |
| 3E0B3HZ | Introduction of Radioactive Substance into Ear, Percutaneous Approach |
| 3E0B3KZ | Introduction of Other Diagnostic Substance into Ear, Percutaneous Approach |
| 3E0B3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Ear, Percutaneous Approach |
| 3E0B3TZ | Introduction of Destructive Agent into Ear, Percutaneous Approach |
| 3E0B704 | Introduction of Liquid Brachytherapy Radioisotope into Ear, Via Natural or Artificial Opening |
| 3E0B705 | Introduction of Other Antineoplastic into Ear, Via Natural or Artificial Opening |
| 3E0B70M | Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Via Natural or Artificial Opening |
| 3E0B728 | Introduction of Oxazolidinones into Ear, Via Natural or Artificial Opening |
| 3E0B729 | Introduction of Other Anti-infective into Ear, Via Natural or Artificial Opening |
| 3E0B73Z | Introduction of Anti-inflammatory into Ear, Via Natural or Artificial Opening |
| 3E0B7BZ | Introduction of Anesthetic Agent into Ear, Via Natural or Artificial Opening |
| 3E0B7GC | Introduction of Other Therapeutic Substance into Ear, Via Natural or Artificial Opening |
| 3E0B7HZ | Introduction of Radioactive Substance into Ear, Via Natural or Artificial Opening |
| 3E0B7KZ | Introduction of Other Diagnostic Substance into Ear, Via Natural or Artificial Opening |
| 3E0B7NZ | Introduction of Analgesics, Hypnotics, Sedatives into Ear, Via Natural or Artificial Opening |
| 3E0B7TZ | Introduction of Destructive Agent into Ear, Via Natural or Artificial Opening |
| 3E0BX04 | Introduction of Liquid Brachytherapy Radioisotope into Ear, External Approach |
| 3E0BX05 | Introduction of Other Antineoplastic into Ear, External Approach |
| 3E0BX0M | Introduction of Antineoplastic, Monoclonal Antibody, into Ear, External Approach |
| 3E0BX28 | Introduction of Oxazolidinones into Ear, External Approach |
| 3E0BX29 | Introduction of Other Anti-infective into Ear, External Approach |
| 3E0BX3Z | Introduction of Anti-inflammatory into Ear, External Approach |
| 3E0BXBZ | Introduction of Anesthetic Agent into Ear, External Approach |
| 3E0BXGC | Introduction of Other Therapeutic Substance into Ear, External Approach |
| 3E0BXHZ | Introduction of Radioactive Substance into Ear, External Approach |
| 3E0BXKZ | Introduction of Other Diagnostic Substance into Ear, External Approach |
| 3E0BXNZ | Introduction of Analgesics, Hypnotics, Sedatives into Ear, External Approach |
| 3E0BXTZ | Introduction of Destructive Agent into Ear, External Approach |
| 3E0C304 | Introduction of Liquid Brachytherapy Radioisotope into Eye, Percutaneous Approach |
| 3E0C305 | Introduction of Other Antineoplastic into Eye, Percutaneous Approach |
| 3E0C30M | Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Percutaneous Approach |
| 3E0C328 | Introduction of Oxazolidinones into Eye, Percutaneous Approach |
| 3E0C329 | Introduction of Other Anti-infective into Eye, Percutaneous Approach |
| 3E0C33Z | Introduction of Anti-inflammatory into Eye, Percutaneous Approach |
| 3E0C3BZ | Introduction of Anesthetic Agent into Eye, Percutaneous Approach |
| 3E0C3GC | Introduction of Other Therapeutic Substance into Eye, Percutaneous Approach |
| 3E0C3HZ | Introduction of Radioactive Substance into Eye, Percutaneous Approach |
| 3E0C3KZ | Introduction of Other Diagnostic Substance into Eye, Percutaneous Approach |
| 3E0C3MZ | Introduction of Pigment into Eye, Percutaneous Approach |
| 3E0C3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Eye, Percutaneous Approach |
| 3E0C3SF | Introduction of Other Gas into Eye, Percutaneous Approach |
| 3E0C3TZ | Introduction of Destructive Agent into Eye, Percutaneous Approach |
| 3E0C704 | Introduction of Liquid Brachytherapy Radioisotope into Eye, Via Natural or Artificial Opening |
| 3E0C705 | Introduction of Other Antineoplastic into Eye, Via Natural or Artificial Opening |
| 3E0C70M | Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Via Natural or Artificial Opening |
| 3E0C728 | Introduction of Oxazolidinones into Eye, Via Natural or Artificial Opening |
| 3E0C729 | Introduction of Other Anti-infective into Eye, Via Natural or Artificial Opening |
| 3E0C73Z | Introduction of Anti-inflammatory into Eye, Via Natural or Artificial Opening |
| 3E0C7BZ | Introduction of Anesthetic Agent into Eye, Via Natural or Artificial Opening |
| 3E0C7GC | Introduction of Other Therapeutic Substance into Eye, Via Natural or Artificial Opening |
| 3E0C7HZ | Introduction of Radioactive Substance into Eye, Via Natural or Artificial Opening |
| 3E0C7KZ | Introduction of Other Diagnostic Substance into Eye, Via Natural or Artificial Opening |
| 3E0C7MZ | Introduction of Pigment into Eye, Via Natural or Artificial Opening |
| 3E0C7NZ | Introduction of Analgesics, Hypnotics, Sedatives into Eye, Via Natural or Artificial Opening |
| 3E0C7SF | Introduction of Other Gas into Eye, Via Natural or Artificial Opening |
| 3E0C7TZ | Introduction of Destructive Agent into Eye, Via Natural or Artificial Opening |
| 3E0CX04 | Introduction of Liquid Brachytherapy Radioisotope into Eye, External Approach |
| 3E0CX05 | Introduction of Other Antineoplastic into Eye, External Approach |
| 3E0CX0M | Introduction of Antineoplastic, Monoclonal Antibody, into Eye, External Approach |
| 3E0CX28 | Introduction of Oxazolidinones into Eye, External Approach |
| 3E0CX29 | Introduction of Other Anti-infective into Eye, External Approach |
| 3E0CX3Z | Introduction of Anti-inflammatory into Eye, External Approach |
| 3E0CXBZ | Introduction of Anesthetic Agent into Eye, External Approach |
| 3E0CXGC | Introduction of Other Therapeutic Substance into Eye, External Approach |
| 3E0CXHZ | Introduction of Radioactive Substance into Eye, External Approach |
| 3E0CXKZ | Introduction of Other Diagnostic Substance into Eye, External Approach |
| 3E0CXMZ | Introduction of Pigment into Eye, External Approach |
| 3E0CXNZ | Introduction of Analgesics, Hypnotics, Sedatives into Eye, External Approach |
| 3E0CXSF | Introduction of Other Gas into Eye, External Approach |
| 3E0CXTZ | Introduction of Destructive Agent into Eye, External Approach |
| 3E0D304 | Introduction of Liquid Brachytherapy Radioisotope into Mouth and Pharynx, Percutaneous Approach |
| 3E0D305 | Introduction of Other Antineoplastic into Mouth and Pharynx, Percutaneous Approach |
| 3E0D30M | Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Percutaneous Approach |
| 3E0D328 | Introduction of Oxazolidinones into Mouth and Pharynx, Percutaneous Approach |
| 3E0D329 | Introduction of Other Anti-infective into Mouth and Pharynx, Percutaneous Approach |
| 3E0D33Z | Introduction of Anti-inflammatory into Mouth and Pharynx, Percutaneous Approach |
| 3E0D34Z | Introduction of Serum, Toxoid and Vaccine into Mouth and Pharynx, Percutaneous Approach |
| 3E0D36Z | Introduction of Nutritional Substance into Mouth and Pharynx, Percutaneous Approach |
| 3E0D37Z | Introduction of Electrolytic and Water Balance Substance into Mouth and Pharynx, Percutaneous Approach |
| 3E0D3BZ | Introduction of Anesthetic Agent into Mouth and Pharynx, Percutaneous Approach |
| 3E0D3GC | Introduction of Other Therapeutic Substance into Mouth and Pharynx, Percutaneous Approach |
| 3E0D3HZ | Introduction of Radioactive Substance into Mouth and Pharynx, Percutaneous Approach |
| 3E0D3KZ | Introduction of Other Diagnostic Substance into Mouth and Pharynx, Percutaneous Approach |
| 3E0D3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Mouth and Pharynx, Percutaneous Approach |
| 3E0D3RZ | Introduction of Antiarrhythmic into Mouth and Pharynx, Percutaneous Approach |
| 3E0D3TZ | Introduction of Destructive Agent into Mouth and Pharynx, Percutaneous Approach |
| 3E0D704 | Introduction of Liquid Brachytherapy Radioisotope into Mouth and Pharynx, Via Natural or Artificial Opening |
| 3E0D705 | Introduction of Other Antineoplastic into Mouth and Pharynx, Via Natural or Artificial Opening |
| 3E0D70M | Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Via Natural or Artificial Opening |
| 3E0D728 | Introduction of Oxazolidinones into Mouth and Pharynx, Via Natural or Artificial Opening |
| 3E0D729 | Introduction of Other Anti-infective into Mouth and Pharynx, Via Natural or Artificial Opening |
| 3E0D73Z | Introduction of Anti-inflammatory into Mouth and Pharynx, Via Natural or Artificial Opening |
| 3E0D74Z | Introduction of Serum, Toxoid and Vaccine into Mouth and Pharynx, Via Natural or Artificial Opening |
| 3E0D76Z | Introduction of Nutritional Substance into Mouth and Pharynx, Via Natural or Artificial Opening |
| 3E0D77Z | Introduction of Electrolytic and Water Balance Substance into Mouth and Pharynx, Via Natural or Artificial Opening |
| 3E0D7BZ | Introduction of Anesthetic Agent into Mouth and Pharynx, Via Natural or Artificial Opening |
| 3E0D7GC | Introduction of Other Therapeutic Substance into Mouth and Pharynx, Via Natural or Artificial Opening |
| 3E0D7HZ | Introduction of Radioactive Substance into Mouth and Pharynx, Via Natural or Artificial Opening |
| 3E0D7KZ | Introduction of Other Diagnostic Substance into Mouth and Pharynx, Via Natural or Artificial Opening |
| 3E0D7NZ | Introduction of Analgesics, Hypnotics, Sedatives into Mouth and Pharynx, Via Natural or Artificial Opening |
| 3E0D7RZ | Introduction of Antiarrhythmic into Mouth and Pharynx, Via Natural or Artificial Opening |
| 3E0D7TZ | Introduction of Destructive Agent into Mouth and Pharynx, Via Natural or Artificial Opening |
| 3E0DX04 | Introduction of Liquid Brachytherapy Radioisotope into Mouth and Pharynx, External Approach |
| 3E0DX05 | Introduction of Other Antineoplastic into Mouth and Pharynx, External Approach |
| 3E0DX0M | Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, External Approach |
| 3E0DX28 | Introduction of Oxazolidinones into Mouth and Pharynx, External Approach |
| 3E0DX29 | Introduction of Other Anti-infective into Mouth and Pharynx, External Approach |
| 3E0DX3Z | Introduction of Anti-inflammatory into Mouth and Pharynx, External Approach |
| 3E0DX4Z | Introduction of Serum, Toxoid and Vaccine into Mouth and Pharynx, External Approach |
| 3E0DX6Z | Introduction of Nutritional Substance into Mouth and Pharynx, External Approach |
| 3E0DX7Z | Introduction of Electrolytic and Water Balance Substance into Mouth and Pharynx, External Approach |
| 3E0DXBZ | Introduction of Anesthetic Agent into Mouth and Pharynx, External Approach |
| 3E0DXGC | Introduction of Other Therapeutic Substance into Mouth and Pharynx, External Approach |
| 3E0DXHZ | Introduction of Radioactive Substance into Mouth and Pharynx, External Approach |
| 3E0DXKZ | Introduction of Other Diagnostic Substance into Mouth and Pharynx, External Approach |
| 3E0DXNZ | Introduction of Analgesics, Hypnotics, Sedatives into Mouth and Pharynx, External Approach |
| 3E0DXRZ | Introduction of Antiarrhythmic into Mouth and Pharynx, External Approach |
| 3E0DXTZ | Introduction of Destructive Agent into Mouth and Pharynx, External Approach |
| 3E0E304 | Introduction of Liquid Brachytherapy Radioisotope into Products of Conception, Percutaneous Approach |
| 3E0E305 | Introduction of Other Antineoplastic into Products of Conception, Percutaneous Approach |
| 3E0E30M | Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Percutaneous Approach |
| 3E0E328 | Introduction of Oxazolidinones into Products of Conception, Percutaneous Approach |
| 3E0E329 | Introduction of Other Anti-infective into Products of Conception, Percutaneous Approach |
| 3E0E33Z | Introduction of Anti-inflammatory into Products of Conception, Percutaneous Approach |
| 3E0E36Z | Introduction of Nutritional Substance into Products of Conception, Percutaneous Approach |
| 3E0E37Z | Introduction of Electrolytic and Water Balance Substance into Products of Conception, Percutaneous Approach |
| 3E0E3BZ | Introduction of Anesthetic Agent into Products of Conception, Percutaneous Approach |
| 3E0E3GC | Introduction of Other Therapeutic Substance into Products of Conception, Percutaneous Approach |
| 3E0E3HZ | Introduction of Radioactive Substance into Products of Conception, Percutaneous Approach |
| 3E0E3KZ | Introduction of Other Diagnostic Substance into Products of Conception, Percutaneous Approach |
| 3E0E3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Products of Conception, Percutaneous Approach |
| 3E0E3SF | Introduction of Other Gas into Products of Conception, Percutaneous Approach |
| 3E0E3TZ | Introduction of Destructive Agent into Products of Conception, Percutaneous Approach |
| 3E0E4GC | Introduction of Other Therapeutic Substance into Products of Conception, Percutaneous Endoscopic Approach |
| 3E0E704 | Introduction of Liquid Brachytherapy Radioisotope into Products of Conception, Via Natural or Artificial Opening |
| 3E0E705 | Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening |
| 3E0E70M | Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening |
| 3E0E728 | Introduction of Oxazolidinones into Products of Conception, Via Natural or Artificial Opening |
| 3E0E729 | Introduction of Other Anti-infective into Products of Conception, Via Natural or Artificial Opening |
| 3E0E73Z | Introduction of Anti-inflammatory into Products of Conception, Via Natural or Artificial Opening |
| 3E0E76Z | Introduction of Nutritional Substance into Products of Conception, Via Natural or Artificial Opening |
| 3E0E77Z | Introduction of Electrolytic and Water Balance Substance into Products of Conception, Via Natural or Artificial Opening |
| 3E0E7BZ | Introduction of Anesthetic Agent into Products of Conception, Via Natural or Artificial Opening |
| 3E0E7GC | Introduction of Other Therapeutic Substance into Products of Conception, Via Natural or Artificial Opening |
| 3E0E7HZ | Introduction of Radioactive Substance into Products of Conception, Via Natural or Artificial Opening |
| 3E0E7KZ | Introduction of Other Diagnostic Substance into Products of Conception, Via Natural or Artificial Opening |
| 3E0E7NZ | Introduction of Analgesics, Hypnotics, Sedatives into Products of Conception, Via Natural or Artificial Opening |
| 3E0E7SF | Introduction of Other Gas into Products of Conception, Via Natural or Artificial Opening |
| 3E0E7TZ | Introduction of Destructive Agent into Products of Conception, Via Natural or Artificial Opening |
| 3E0E804 | Introduction of Liquid Brachytherapy Radioisotope into Products of Conception, Via Natural or Artificial Opening Endoscopic |
| 3E0E805 | Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening Endoscopic |
| 3E0E80M | Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening Endoscopic |
| 3E0E828 | Introduction of Oxazolidinones into Products of Conception, Via Natural or Artificial Opening Endoscopic |
| 3E0E829 | Introduction of Other Anti-infective into Products of Conception, Via Natural or Artificial Opening Endoscopic |
| 3E0E83Z | Introduction of Anti-inflammatory into Products of Conception, Via Natural or Artificial Opening Endoscopic |
| 3E0E86Z | Introduction of Nutritional Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic |
| 3E0E87Z | Introduction of Electrolytic and Water Balance Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic |
| 3E0E8BZ | Introduction of Anesthetic Agent into Products of Conception, Via Natural or Artificial Opening Endoscopic |
| 3E0E8GC | Introduction of Other Therapeutic Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic |
| 3E0E8HZ | Introduction of Radioactive Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic |
| 3E0E8KZ | Introduction of Other Diagnostic Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic |
| 3E0E8NZ | Introduction of Analgesics, Hypnotics, Sedatives into Products of Conception, Via Natural or Artificial Opening Endoscopic |
| 3E0E8SF | Introduction of Other Gas into Products of Conception, Via Natural or Artificial Opening Endoscopic |
| 3E0E8TZ | Introduction of Destructive Agent into Products of Conception, Via Natural or Artificial Opening Endoscopic |
| 3E0F304 | Introduction of Liquid Brachytherapy Radioisotope into Respiratory Tract, Percutaneous Approach |
| 3E0F305 | Introduction of Other Antineoplastic into Respiratory Tract, Percutaneous Approach |
| 3E0F30M | Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Percutaneous Approach |
| 3E0F328 | Introduction of Oxazolidinones into Respiratory Tract, Percutaneous Approach |
| 3E0F329 | Introduction of Other Anti-infective into Respiratory Tract, Percutaneous Approach |
| 3E0F33Z | Introduction of Anti-inflammatory into Respiratory Tract, Percutaneous Approach |
| 3E0F36Z | Introduction of Nutritional Substance into Respiratory Tract, Percutaneous Approach |
| 3E0F37Z | Introduction of Electrolytic and Water Balance Substance into Respiratory Tract, Percutaneous Approach |
| 3E0F3BZ | Introduction of Anesthetic Agent into Respiratory Tract, Percutaneous Approach |
| 3E0F3GC | Introduction of Other Therapeutic Substance into Respiratory Tract, Percutaneous Approach |
| 3E0F3HZ | Introduction of Radioactive Substance into Respiratory Tract, Percutaneous Approach |
| 3E0F3KZ | Introduction of Other Diagnostic Substance into Respiratory Tract, Percutaneous Approach |
| 3E0F3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Respiratory Tract, Percutaneous Approach |
| 3E0F3SD | Introduction of Nitric Oxide Gas into Respiratory Tract, Percutaneous Approach |
| 3E0F3SF | Introduction of Other Gas into Respiratory Tract, Percutaneous Approach |
| 3E0F3TZ | Introduction of Destructive Agent into Respiratory Tract, Percutaneous Approach |
| 3E0F4GC | Introduction of Other Therapeutic Substance into Respiratory Tract, Percutaneous Endoscopic Approach |
| 3E0F704 | Introduction of Liquid Brachytherapy Radioisotope into Respiratory Tract, Via Natural or Artificial Opening |
| 3E0F705 | Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening |
| 3E0F70M | Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening |
| 3E0F728 | Introduction of Oxazolidinones into Respiratory Tract, Via Natural or Artificial Opening |
| 3E0F729 | Introduction of Other Anti-infective into Respiratory Tract, Via Natural or Artificial Opening |
| 3E0F73Z | Introduction of Anti-inflammatory into Respiratory Tract, Via Natural or Artificial Opening |
| 3E0F76Z | Introduction of Nutritional Substance into Respiratory Tract, Via Natural or Artificial Opening |
| 3E0F77Z | Introduction of Electrolytic and Water Balance Substance into Respiratory Tract, Via Natural or Artificial Opening |
| 3E0F7BZ | Introduction of Anesthetic Agent into Respiratory Tract, Via Natural or Artificial Opening |
| 3E0F7GC | Introduction of Other Therapeutic Substance into Respiratory Tract, Via Natural or Artificial Opening |
| 3E0F7HZ | Introduction of Radioactive Substance into Respiratory Tract, Via Natural or Artificial Opening |
| 3E0F7KZ | Introduction of Other Diagnostic Substance into Respiratory Tract, Via Natural or Artificial Opening |
| 3E0F7NZ | Introduction of Analgesics, Hypnotics, Sedatives into Respiratory Tract, Via Natural or Artificial Opening |
| 3E0F7SD | Introduction of Nitric Oxide Gas into Respiratory Tract, Via Natural or Artificial Opening |
| 3E0F7SF | Introduction of Other Gas into Respiratory Tract, Via Natural or Artificial Opening |
| 3E0F7TZ | Introduction of Destructive Agent into Respiratory Tract, Via Natural or Artificial Opening |
| 3E0F804 | Introduction of Liquid Brachytherapy Radioisotope into Respiratory Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0F805 | Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0F80M | Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0F828 | Introduction of Oxazolidinones into Respiratory Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0F829 | Introduction of Other Anti-infective into Respiratory Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0F83Z | Introduction of Anti-inflammatory into Respiratory Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0F86Z | Introduction of Nutritional Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0F87Z | Introduction of Electrolytic and Water Balance Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0F8BZ | Introduction of Anesthetic Agent into Respiratory Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0F8GC | Introduction of Other Therapeutic Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0F8HZ | Introduction of Radioactive Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0F8KZ | Introduction of Other Diagnostic Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0F8NZ | Introduction of Analgesics, Hypnotics, Sedatives into Respiratory Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0F8SD | Introduction of Nitric Oxide Gas into Respiratory Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0F8SF | Introduction of Other Gas into Respiratory Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0F8TZ | Introduction of Destructive Agent into Respiratory Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0G304 | Introduction of Liquid Brachytherapy Radioisotope into Upper GI, Percutaneous Approach |
| 3E0G305 | Introduction of Other Antineoplastic into Upper GI, Percutaneous Approach |
| 3E0G30M | Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Percutaneous Approach |
| 3E0G328 | Introduction of Oxazolidinones into Upper GI, Percutaneous Approach |
| 3E0G329 | Introduction of Other Anti-infective into Upper GI, Percutaneous Approach |
| 3E0G33Z | Introduction of Anti-inflammatory into Upper GI, Percutaneous Approach |
| 3E0G36Z | Introduction of Nutritional Substance into Upper GI, Percutaneous Approach |
| 3E0G37Z | Introduction of Electrolytic and Water Balance Substance into Upper GI, Percutaneous Approach |
| 3E0G3BZ | Introduction of Anesthetic Agent into Upper GI, Percutaneous Approach |
| 3E0G3GC | Introduction of Other Therapeutic Substance into Upper GI, Percutaneous Approach |
| 3E0G3HZ | Introduction of Radioactive Substance into Upper GI, Percutaneous Approach |
| 3E0G3KZ | Introduction of Other Diagnostic Substance into Upper GI, Percutaneous Approach |
| 3E0G3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Upper GI, Percutaneous Approach |
| 3E0G3SF | Introduction of Other Gas into Upper GI, Percutaneous Approach |
| 3E0G3TZ | Introduction of Destructive Agent into Upper GI, Percutaneous Approach |
| 3E0G4GC | Introduction of Other Therapeutic Substance into Upper GI, Percutaneous Endoscopic Approach |
| 3E0G704 | Introduction of Liquid Brachytherapy Radioisotope into Upper GI, Via Natural or Artificial Opening |
| 3E0G705 | Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening |
| 3E0G70M | Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening |
| 3E0G728 | Introduction of Oxazolidinones into Upper GI, Via Natural or Artificial Opening |
| 3E0G729 | Introduction of Other Anti-infective into Upper GI, Via Natural or Artificial Opening |
| 3E0G73Z | Introduction of Anti-inflammatory into Upper GI, Via Natural or Artificial Opening |
| 3E0G76Z | Introduction of Nutritional Substance into Upper GI, Via Natural or Artificial Opening |
| 3E0G77Z | Introduction of Electrolytic and Water Balance Substance into Upper GI, Via Natural or Artificial Opening |
| 3E0G7BZ | Introduction of Anesthetic Agent into Upper GI, Via Natural or Artificial Opening |
| 3E0G7GC | Introduction of Other Therapeutic Substance into Upper GI, Via Natural or Artificial Opening |
| 3E0G7HZ | Introduction of Radioactive Substance into Upper GI, Via Natural or Artificial Opening |
| 3E0G7KZ | Introduction of Other Diagnostic Substance into Upper GI, Via Natural or Artificial Opening |
| 3E0G7NZ | Introduction of Analgesics, Hypnotics, Sedatives into Upper GI, Via Natural or Artificial Opening |
| 3E0G7SF | Introduction of Other Gas into Upper GI, Via Natural or Artificial Opening |
| 3E0G7TZ | Introduction of Destructive Agent into Upper GI, Via Natural or Artificial Opening |
| 3E0G804 | Introduction of Liquid Brachytherapy Radioisotope into Upper GI, Via Natural or Artificial Opening Endoscopic |
| 3E0G805 | Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening Endoscopic |
| 3E0G80M | Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening Endoscopic |
| 3E0G828 | Introduction of Oxazolidinones into Upper GI, Via Natural or Artificial Opening Endoscopic |
| 3E0G829 | Introduction of Other Anti-infective into Upper GI, Via Natural or Artificial Opening Endoscopic |
| 3E0G83Z | Introduction of Anti-inflammatory into Upper GI, Via Natural or Artificial Opening Endoscopic |
| 3E0G86Z | Introduction of Nutritional Substance into Upper GI, Via Natural or Artificial Opening Endoscopic |
| 3E0G87Z | Introduction of Electrolytic and Water Balance Substance into Upper GI, Via Natural or Artificial Opening Endoscopic |
| 3E0G8BZ | Introduction of Anesthetic Agent into Upper GI, Via Natural or Artificial Opening Endoscopic |
| 3E0G8GC | Introduction of Other Therapeutic Substance into Upper GI, Via Natural or Artificial Opening Endoscopic |
| 3E0G8HZ | Introduction of Radioactive Substance into Upper GI, Via Natural or Artificial Opening Endoscopic |
| 3E0G8KZ | Introduction of Other Diagnostic Substance into Upper GI, Via Natural or Artificial Opening Endoscopic |
| 3E0G8NZ | Introduction of Analgesics, Hypnotics, Sedatives into Upper GI, Via Natural or Artificial Opening Endoscopic |
| 3E0G8SF | Introduction of Other Gas into Upper GI, Via Natural or Artificial Opening Endoscopic |
| 3E0G8TZ | Introduction of Destructive Agent into Upper GI, Via Natural or Artificial Opening Endoscopic |
| 3E0H304 | Introduction of Liquid Brachytherapy Radioisotope into Lower GI, Percutaneous Approach |
| 3E0H305 | Introduction of Other Antineoplastic into Lower GI, Percutaneous Approach |
| 3E0H30M | Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Percutaneous Approach |
| 3E0H328 | Introduction of Oxazolidinones into Lower GI, Percutaneous Approach |
| 3E0H329 | Introduction of Other Anti-infective into Lower GI, Percutaneous Approach |
| 3E0H33Z | Introduction of Anti-inflammatory into Lower GI, Percutaneous Approach |
| 3E0H36Z | Introduction of Nutritional Substance into Lower GI, Percutaneous Approach |
| 3E0H37Z | Introduction of Electrolytic and Water Balance Substance into Lower GI, Percutaneous Approach |
| 3E0H3BZ | Introduction of Anesthetic Agent into Lower GI, Percutaneous Approach |
| 3E0H3GC | Introduction of Other Therapeutic Substance into Lower GI, Percutaneous Approach |
| 3E0H3HZ | Introduction of Radioactive Substance into Lower GI, Percutaneous Approach |
| 3E0H3KZ | Introduction of Other Diagnostic Substance into Lower GI, Percutaneous Approach |
| 3E0H3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Lower GI, Percutaneous Approach |
| 3E0H3SF | Introduction of Other Gas into Lower GI, Percutaneous Approach |
| 3E0H3TZ | Introduction of Destructive Agent into Lower GI, Percutaneous Approach |
| 3E0H4GC | Introduction of Other Therapeutic Substance into Lower GI, Percutaneous Endoscopic Approach |
| 3E0H704 | Introduction of Liquid Brachytherapy Radioisotope into Lower GI, Via Natural or Artificial Opening |
| 3E0H705 | Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening |
| 3E0H70M | Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening |
| 3E0H728 | Introduction of Oxazolidinones into Lower GI, Via Natural or Artificial Opening |
| 3E0H729 | Introduction of Other Anti-infective into Lower GI, Via Natural or Artificial Opening |
| 3E0H73Z | Introduction of Anti-inflammatory into Lower GI, Via Natural or Artificial Opening |
| 3E0H76Z | Introduction of Nutritional Substance into Lower GI, Via Natural or Artificial Opening |
| 3E0H77Z | Introduction of Electrolytic and Water Balance Substance into Lower GI, Via Natural or Artificial Opening |
| 3E0H7BZ | Introduction of Anesthetic Agent into Lower GI, Via Natural or Artificial Opening |
| 3E0H7GC | Introduction of Other Therapeutic Substance into Lower GI, Via Natural or Artificial Opening |
| 3E0H7HZ | Introduction of Radioactive Substance into Lower GI, Via Natural or Artificial Opening |
| 3E0H7KZ | Introduction of Other Diagnostic Substance into Lower GI, Via Natural or Artificial Opening |
| 3E0H7NZ | Introduction of Analgesics, Hypnotics, Sedatives into Lower GI, Via Natural or Artificial Opening |
| 3E0H7SF | Introduction of Other Gas into Lower GI, Via Natural or Artificial Opening |
| 3E0H7TZ | Introduction of Destructive Agent into Lower GI, Via Natural or Artificial Opening |
| 3E0H804 | Introduction of Liquid Brachytherapy Radioisotope into Lower GI, Via Natural or Artificial Opening Endoscopic |
| 3E0H805 | Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening Endoscopic |
| 3E0H80M | Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening Endoscopic |
| 3E0H828 | Introduction of Oxazolidinones into Lower GI, Via Natural or Artificial Opening Endoscopic |
| 3E0H829 | Introduction of Other Anti-infective into Lower GI, Via Natural or Artificial Opening Endoscopic |
| 3E0H83Z | Introduction of Anti-inflammatory into Lower GI, Via Natural or Artificial Opening Endoscopic |
| 3E0H86Z | Introduction of Nutritional Substance into Lower GI, Via Natural or Artificial Opening Endoscopic |
| 3E0H87Z | Introduction of Electrolytic and Water Balance Substance into Lower GI, Via Natural or Artificial Opening Endoscopic |
| 3E0H8BZ | Introduction of Anesthetic Agent into Lower GI, Via Natural or Artificial Opening Endoscopic |
| 3E0H8GC | Introduction of Other Therapeutic Substance into Lower GI, Via Natural or Artificial Opening Endoscopic |
| 3E0H8HZ | Introduction of Radioactive Substance into Lower GI, Via Natural or Artificial Opening Endoscopic |
| 3E0H8KZ | Introduction of Other Diagnostic Substance into Lower GI, Via Natural or Artificial Opening Endoscopic |
| 3E0H8NZ | Introduction of Analgesics, Hypnotics, Sedatives into Lower GI, Via Natural or Artificial Opening Endoscopic |
| 3E0H8SF | Introduction of Other Gas into Lower GI, Via Natural or Artificial Opening Endoscopic |
| 3E0H8TZ | Introduction of Destructive Agent into Lower GI, Via Natural or Artificial Opening Endoscopic |
| 3E0J304 | Introduction of Liquid Brachytherapy Radioisotope into Biliary and Pancreatic Tract, Percutaneous Approach |
| 3E0J305 | Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Percutaneous Approach |
| 3E0J30M | Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Percutaneous Approach |
| 3E0J328 | Introduction of Oxazolidinones into Biliary and Pancreatic Tract, Percutaneous Approach |
| 3E0J329 | Introduction of Other Anti-infective into Biliary and Pancreatic Tract, Percutaneous Approach |
| 3E0J33Z | Introduction of Anti-inflammatory into Biliary and Pancreatic Tract, Percutaneous Approach |
| 3E0J36Z | Introduction of Nutritional Substance into Biliary and Pancreatic Tract, Percutaneous Approach |
| 3E0J37Z | Introduction of Electrolytic and Water Balance Substance into Biliary and Pancreatic Tract, Percutaneous Approach |
| 3E0J3BZ | Introduction of Anesthetic Agent into Biliary and Pancreatic Tract, Percutaneous Approach |
| 3E0J3GC | Introduction of Other Therapeutic Substance into Biliary and Pancreatic Tract, Percutaneous Approach |
| 3E0J3HZ | Introduction of Radioactive Substance into Biliary and Pancreatic Tract, Percutaneous Approach |
| 3E0J3KZ | Introduction of Other Diagnostic Substance into Biliary and Pancreatic Tract, Percutaneous Approach |
| 3E0J3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Biliary and Pancreatic Tract, Percutaneous Approach |
| 3E0J3SF | Introduction of Other Gas into Biliary and Pancreatic Tract, Percutaneous Approach |
| 3E0J3TZ | Introduction of Destructive Agent into Biliary and Pancreatic Tract, Percutaneous Approach |
| 3E0J3U0 | Introduction of Autologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Percutaneous Approach |
| 3E0J3U1 | Introduction of Nonautologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Percutaneous Approach |
| 3E0J4GC | Introduction of Other Therapeutic Substance into Biliary and Pancreatic Tract, Percutaneous Endoscopic Approach |
| 3E0J704 | Introduction of Liquid Brachytherapy Radioisotope into Biliary and Pancreatic Tract, Via Natural or Artificial Opening |
| 3E0J705 | Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening |
| 3E0J70M | Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening |
| 3E0J728 | Introduction of Oxazolidinones into Biliary and Pancreatic Tract, Via Natural or Artificial Opening |
| 3E0J729 | Introduction of Other Anti-infective into Biliary and Pancreatic Tract, Via Natural or Artificial Opening |
| 3E0J73Z | Introduction of Anti-inflammatory into Biliary and Pancreatic Tract, Via Natural or Artificial Opening |
| 3E0J76Z | Introduction of Nutritional Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening |
| 3E0J77Z | Introduction of Electrolytic and Water Balance Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening |
| 3E0J7BZ | Introduction of Anesthetic Agent into Biliary and Pancreatic Tract, Via Natural or Artificial Opening |
| 3E0J7GC | Introduction of Other Therapeutic Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening |
| 3E0J7HZ | Introduction of Radioactive Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening |
| 3E0J7KZ | Introduction of Other Diagnostic Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening |
| 3E0J7NZ | Introduction of Analgesics, Hypnotics, Sedatives into Biliary and Pancreatic Tract, Via Natural or Artificial Opening |
| 3E0J7SF | Introduction of Other Gas into Biliary and Pancreatic Tract, Via Natural or Artificial Opening |
| 3E0J7TZ | Introduction of Destructive Agent into Biliary and Pancreatic Tract, Via Natural or Artificial Opening |
| 3E0J7U0 | Introduction of Autologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Opening |
| 3E0J7U1 | Introduction of Nonautologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Opening |
| 3E0J804 | Introduction of Liquid Brachytherapy Radioisotope into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0J805 | Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0J80M | Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0J828 | Introduction of Oxazolidinones into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0J829 | Introduction of Other Anti-infective into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0J83Z | Introduction of Anti-inflammatory into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0J86Z | Introduction of Nutritional Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0J87Z | Introduction of Electrolytic and Water Balance Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0J8BZ | Introduction of Anesthetic Agent into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0J8GC | Introduction of Other Therapeutic Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0J8HZ | Introduction of Radioactive Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0J8KZ | Introduction of Other Diagnostic Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0J8NZ | Introduction of Analgesics, Hypnotics, Sedatives into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0J8SF | Introduction of Other Gas into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0J8TZ | Introduction of Destructive Agent into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0J8U0 | Introduction of Autologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0J8U1 | Introduction of Nonautologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0K304 | Introduction of Liquid Brachytherapy Radioisotope into Genitourinary Tract, Percutaneous Approach |
| 3E0K305 | Introduction of Other Antineoplastic into Genitourinary Tract, Percutaneous Approach |
| 3E0K30M | Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Percutaneous Approach |
| 3E0K328 | Introduction of Oxazolidinones into Genitourinary Tract, Percutaneous Approach |
| 3E0K329 | Introduction of Other Anti-infective into Genitourinary Tract, Percutaneous Approach |
| 3E0K33Z | Introduction of Anti-inflammatory into Genitourinary Tract, Percutaneous Approach |
| 3E0K36Z | Introduction of Nutritional Substance into Genitourinary Tract, Percutaneous Approach |
| 3E0K37Z | Introduction of Electrolytic and Water Balance Substance into Genitourinary Tract, Percutaneous Approach |
| 3E0K3BZ | Introduction of Anesthetic Agent into Genitourinary Tract, Percutaneous Approach |
| 3E0K3GC | Introduction of Other Therapeutic Substance into Genitourinary Tract, Percutaneous Approach |
| 3E0K3HZ | Introduction of Radioactive Substance into Genitourinary Tract, Percutaneous Approach |
| 3E0K3KZ | Introduction of Other Diagnostic Substance into Genitourinary Tract, Percutaneous Approach |
| 3E0K3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Genitourinary Tract, Percutaneous Approach |
| 3E0K3SF | Introduction of Other Gas into Genitourinary Tract, Percutaneous Approach |
| 3E0K3TZ | Introduction of Destructive Agent into Genitourinary Tract, Percutaneous Approach |
| 3E0K4GC | Introduction of Other Therapeutic Substance into Genitourinary Tract, Percutaneous Endoscopic Approach |
| 3E0K704 | Introduction of Liquid Brachytherapy Radioisotope into Genitourinary Tract, Via Natural or Artificial Opening |
| 3E0K705 | Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening |
| 3E0K70M | Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening |
| 3E0K728 | Introduction of Oxazolidinones into Genitourinary Tract, Via Natural or Artificial Opening |
| 3E0K729 | Introduction of Other Anti-infective into Genitourinary Tract, Via Natural or Artificial Opening |
| 3E0K73Z | Introduction of Anti-inflammatory into Genitourinary Tract, Via Natural or Artificial Opening |
| 3E0K76Z | Introduction of Nutritional Substance into Genitourinary Tract, Via Natural or Artificial Opening |
| 3E0K77Z | Introduction of Electrolytic and Water Balance Substance into Genitourinary Tract, Via Natural or Artificial Opening |
| 3E0K7BZ | Introduction of Anesthetic Agent into Genitourinary Tract, Via Natural or Artificial Opening |
| 3E0K7GC | Introduction of Other Therapeutic Substance into Genitourinary Tract, Via Natural or Artificial Opening |
| 3E0K7HZ | Introduction of Radioactive Substance into Genitourinary Tract, Via Natural or Artificial Opening |
| 3E0K7KZ | Introduction of Other Diagnostic Substance into Genitourinary Tract, Via Natural or Artificial Opening |
| 3E0K7NZ | Introduction of Analgesics, Hypnotics, Sedatives into Genitourinary Tract, Via Natural or Artificial Opening |
| 3E0K7SF | Introduction of Other Gas into Genitourinary Tract, Via Natural or Artificial Opening |
| 3E0K7TZ | Introduction of Destructive Agent into Genitourinary Tract, Via Natural or Artificial Opening |
| 3E0K804 | Introduction of Liquid Brachytherapy Radioisotope into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0K805 | Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0K80M | Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0K828 | Introduction of Oxazolidinones into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0K829 | Introduction of Other Anti-infective into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0K83Z | Introduction of Anti-inflammatory into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0K86Z | Introduction of Nutritional Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0K87Z | Introduction of Electrolytic and Water Balance Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0K8BZ | Introduction of Anesthetic Agent into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0K8GC | Introduction of Other Therapeutic Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0K8HZ | Introduction of Radioactive Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0K8KZ | Introduction of Other Diagnostic Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0K8NZ | Introduction of Analgesics, Hypnotics, Sedatives into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0K8SF | Introduction of Other Gas into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0K8TZ | Introduction of Destructive Agent into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic |
| 3E0L05Z | Introduction of Adhesion Barrier into Pleural Cavity, Open Approach |
| 3E0L304 | Introduction of Liquid Brachytherapy Radioisotope into Pleural Cavity, Percutaneous Approach |
| 3E0L305 | Introduction of Other Antineoplastic into Pleural Cavity, Percutaneous Approach |
| 3E0L30M | Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Percutaneous Approach |
| 3E0L317 | Introduction of Other Thrombolytic into Pleural Cavity, Percutaneous Approach |
| 3E0L328 | Introduction of Oxazolidinones into Pleural Cavity, Percutaneous Approach |
| 3E0L329 | Introduction of Other Anti-infective into Pleural Cavity, Percutaneous Approach |
| 3E0L33Z | Introduction of Anti-inflammatory into Pleural Cavity, Percutaneous Approach |
| 3E0L35Z | Introduction of Adhesion Barrier into Pleural Cavity, Percutaneous Approach |
| 3E0L36Z | Introduction of Nutritional Substance into Pleural Cavity, Percutaneous Approach |
| 3E0L37Z | Introduction of Electrolytic and Water Balance Substance into Pleural Cavity, Percutaneous Approach |
| 3E0L3BZ | Introduction of Anesthetic Agent into Pleural Cavity, Percutaneous Approach |
| 3E0L3GC | Introduction of Other Therapeutic Substance into Pleural Cavity, Percutaneous Approach |
| 3E0L3HZ | Introduction of Radioactive Substance into Pleural Cavity, Percutaneous Approach |
| 3E0L3KZ | Introduction of Other Diagnostic Substance into Pleural Cavity, Percutaneous Approach |
| 3E0L3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Pleural Cavity, Percutaneous Approach |
| 3E0L3SF | Introduction of Other Gas into Pleural Cavity, Percutaneous Approach |
| 3E0L3TZ | Introduction of Destructive Agent into Pleural Cavity, Percutaneous Approach |
| 3E0L45Z | Introduction of Adhesion Barrier into Pleural Cavity, Percutaneous Endoscopic Approach |
| 3E0L4GC | Introduction of Other Therapeutic Substance into Pleural Cavity, Percutaneous Endoscopic Approach |
| 3E0L704 | Introduction of Liquid Brachytherapy Radioisotope into Pleural Cavity, Via Natural or Artificial Opening |
| 3E0L705 | Introduction of Other Antineoplastic into Pleural Cavity, Via Natural or Artificial Opening |
| 3E0L70M | Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Via Natural or Artificial Opening |
| 3E0L7SF | Introduction of Other Gas into Pleural Cavity, Via Natural or Artificial Opening |
| 3E0M05Z | Introduction of Adhesion Barrier into Peritoneal Cavity, Open Approach |
| 3E0M304 | Introduction of Liquid Brachytherapy Radioisotope into Peritoneal Cavity, Percutaneous Approach |
| 3E0M305 | Introduction of Other Antineoplastic into Peritoneal Cavity, Percutaneous Approach |
| 3E0M30M | Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Percutaneous Approach |
| 3E0M30Y | Introduction of Hyperthermic Antineoplastic into Peritoneal Cavity, Percutaneous Approach |
| 3E0M328 | Introduction of Oxazolidinones into Peritoneal Cavity, Percutaneous Approach |
| 3E0M329 | Introduction of Other Anti-infective into Peritoneal Cavity, Percutaneous Approach |
| 3E0M33Z | Introduction of Anti-inflammatory into Peritoneal Cavity, Percutaneous Approach |
| 3E0M35Z | Introduction of Adhesion Barrier into Peritoneal Cavity, Percutaneous Approach |
| 3E0M36Z | Introduction of Nutritional Substance into Peritoneal Cavity, Percutaneous Approach |
| 3E0M37Z | Introduction of Electrolytic and Water Balance Substance into Peritoneal Cavity, Percutaneous Approach |
| 3E0M3BZ | Introduction of Anesthetic Agent into Peritoneal Cavity, Percutaneous Approach |
| 3E0M3GC | Introduction of Other Therapeutic Substance into Peritoneal Cavity, Percutaneous Approach |
| 3E0M3HZ | Introduction of Radioactive Substance into Peritoneal Cavity, Percutaneous Approach |
| 3E0M3KZ | Introduction of Other Diagnostic Substance into Peritoneal Cavity, Percutaneous Approach |
| 3E0M3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Peritoneal Cavity, Percutaneous Approach |
| 3E0M3SF | Introduction of Other Gas into Peritoneal Cavity, Percutaneous Approach |
| 3E0M3TZ | Introduction of Destructive Agent into Peritoneal Cavity, Percutaneous Approach |
| 3E0M45Z | Introduction of Adhesion Barrier into Peritoneal Cavity, Percutaneous Endoscopic Approach |
| 3E0M4GC | Introduction of Other Therapeutic Substance into Peritoneal Cavity, Percutaneous Endoscopic Approach |
| 3E0M704 | Introduction of Liquid Brachytherapy Radioisotope into Peritoneal Cavity, Via Natural or Artificial Opening |
| 3E0M705 | Introduction of Other Antineoplastic into Peritoneal Cavity, Via Natural or Artificial Opening |
| 3E0M70M | Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Via Natural or Artificial Opening |
| 3E0M7SF | Introduction of Other Gas into Peritoneal Cavity, Via Natural or Artificial Opening |
| 3E0N304 | Introduction of Liquid Brachytherapy Radioisotope into Male Reproductive, Percutaneous Approach |
| 3E0N305 | Introduction of Other Antineoplastic into Male Reproductive, Percutaneous Approach |
| 3E0N30M | Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Percutaneous Approach |
| 3E0N328 | Introduction of Oxazolidinones into Male Reproductive, Percutaneous Approach |
| 3E0N329 | Introduction of Other Anti-infective into Male Reproductive, Percutaneous Approach |
| 3E0N33Z | Introduction of Anti-inflammatory into Male Reproductive, Percutaneous Approach |
| 3E0N36Z | Introduction of Nutritional Substance into Male Reproductive, Percutaneous Approach |
| 3E0N37Z | Introduction of Electrolytic and Water Balance Substance into Male Reproductive, Percutaneous Approach |
| 3E0N3BZ | Introduction of Anesthetic Agent into Male Reproductive, Percutaneous Approach |
| 3E0N3GC | Introduction of Other Therapeutic Substance into Male Reproductive, Percutaneous Approach |
| 3E0N3HZ | Introduction of Radioactive Substance into Male Reproductive, Percutaneous Approach |
| 3E0N3KZ | Introduction of Other Diagnostic Substance into Male Reproductive, Percutaneous Approach |
| 3E0N3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Male Reproductive, Percutaneous Approach |
| 3E0N3SF | Introduction of Other Gas into Male Reproductive, Percutaneous Approach |
| 3E0N3TZ | Introduction of Destructive Agent into Male Reproductive, Percutaneous Approach |
| 3E0N4GC | Introduction of Other Therapeutic Substance into Male Reproductive, Percutaneous Endoscopic Approach |
| 3E0N704 | Introduction of Liquid Brachytherapy Radioisotope into Male Reproductive, Via Natural or Artificial Opening |
| 3E0N705 | Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening |
| 3E0N70M | Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening |
| 3E0N728 | Introduction of Oxazolidinones into Male Reproductive, Via Natural or Artificial Opening |
| 3E0N729 | Introduction of Other Anti-infective into Male Reproductive, Via Natural or Artificial Opening |
| 3E0N73Z | Introduction of Anti-inflammatory into Male Reproductive, Via Natural or Artificial Opening |
| 3E0N76Z | Introduction of Nutritional Substance into Male Reproductive, Via Natural or Artificial Opening |
| 3E0N77Z | Introduction of Electrolytic and Water Balance Substance into Male Reproductive, Via Natural or Artificial Opening |
| 3E0N7BZ | Introduction of Anesthetic Agent into Male Reproductive, Via Natural or Artificial Opening |
| 3E0N7GC | Introduction of Other Therapeutic Substance into Male Reproductive, Via Natural or Artificial Opening |
| 3E0N7HZ | Introduction of Radioactive Substance into Male Reproductive, Via Natural or Artificial Opening |
| 3E0N7KZ | Introduction of Other Diagnostic Substance into Male Reproductive, Via Natural or Artificial Opening |
| 3E0N7NZ | Introduction of Analgesics, Hypnotics, Sedatives into Male Reproductive, Via Natural or Artificial Opening |
| 3E0N7SF | Introduction of Other Gas into Male Reproductive, Via Natural or Artificial Opening |
| 3E0N7TZ | Introduction of Destructive Agent into Male Reproductive, Via Natural or Artificial Opening |
| 3E0N804 | Introduction of Liquid Brachytherapy Radioisotope into Male Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0N805 | Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0N80M | Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0N828 | Introduction of Oxazolidinones into Male Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0N829 | Introduction of Other Anti-infective into Male Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0N83Z | Introduction of Anti-inflammatory into Male Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0N86Z | Introduction of Nutritional Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0N87Z | Introduction of Electrolytic and Water Balance Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0N8BZ | Introduction of Anesthetic Agent into Male Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0N8GC | Introduction of Other Therapeutic Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0N8HZ | Introduction of Radioactive Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0N8KZ | Introduction of Other Diagnostic Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0N8NZ | Introduction of Analgesics, Hypnotics, Sedatives into Male Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0N8SF | Introduction of Other Gas into Male Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0N8TZ | Introduction of Destructive Agent into Male Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0P05Z | Introduction of Adhesion Barrier into Female Reproductive, Open Approach |
| 3E0P304 | Introduction of Liquid Brachytherapy Radioisotope into Female Reproductive, Percutaneous Approach |
| 3E0P305 | Introduction of Other Antineoplastic into Female Reproductive, Percutaneous Approach |
| 3E0P30M | Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Percutaneous Approach |
| 3E0P328 | Introduction of Oxazolidinones into Female Reproductive, Percutaneous Approach |
| 3E0P329 | Introduction of Other Anti-infective into Female Reproductive, Percutaneous Approach |
| 3E0P33Z | Introduction of Anti-inflammatory into Female Reproductive, Percutaneous Approach |
| 3E0P35Z | Introduction of Adhesion Barrier into Female Reproductive, Percutaneous Approach |
| 3E0P36Z | Introduction of Nutritional Substance into Female Reproductive, Percutaneous Approach |
| 3E0P37Z | Introduction of Electrolytic and Water Balance Substance into Female Reproductive, Percutaneous Approach |
| 3E0P3BZ | Introduction of Anesthetic Agent into Female Reproductive, Percutaneous Approach |
| 3E0P3GC | Introduction of Other Therapeutic Substance into Female Reproductive, Percutaneous Approach |
| 3E0P3HZ | Introduction of Radioactive Substance into Female Reproductive, Percutaneous Approach |
| 3E0P3KZ | Introduction of Other Diagnostic Substance into Female Reproductive, Percutaneous Approach |
| 3E0P3LZ | Introduction of Sperm into Female Reproductive, Percutaneous Approach |
| 3E0P3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Female Reproductive, Percutaneous Approach |
| 3E0P3Q0 | Introduction of Autologous Fertilized Ovum into Female Reproductive, Percutaneous Approach |
| 3E0P3Q1 | Introduction of Nonautologous Fertilized Ovum into Female Reproductive, Percutaneous Approach |
| 3E0P3SF | Introduction of Other Gas into Female Reproductive, Percutaneous Approach |
| 3E0P3TZ | Introduction of Destructive Agent into Female Reproductive, Percutaneous Approach |
| 3E0P3VZ | Introduction of Hormone into Female Reproductive, Percutaneous Approach |
| 3E0P45Z | Introduction of Adhesion Barrier into Female Reproductive, Percutaneous Endoscopic Approach |
| 3E0P4GC | Introduction of Other Therapeutic Substance into Female Reproductive, Percutaneous Endoscopic Approach |
| 3E0P704 | Introduction of Liquid Brachytherapy Radioisotope into Female Reproductive, Via Natural or Artificial Opening |
| 3E0P705 | Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening |
| 3E0P70M | Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening |
| 3E0P728 | Introduction of Oxazolidinones into Female Reproductive, Via Natural or Artificial Opening |
| 3E0P729 | Introduction of Other Anti-infective into Female Reproductive, Via Natural or Artificial Opening |
| 3E0P73Z | Introduction of Anti-inflammatory into Female Reproductive, Via Natural or Artificial Opening |
| 3E0P76Z | Introduction of Nutritional Substance into Female Reproductive, Via Natural or Artificial Opening |
| 3E0P77Z | Introduction of Electrolytic and Water Balance Substance into Female Reproductive, Via Natural or Artificial Opening |
| 3E0P7BZ | Introduction of Anesthetic Agent into Female Reproductive, Via Natural or Artificial Opening |
| 3E0P7GC | Introduction of Other Therapeutic Substance into Female Reproductive, Via Natural or Artificial Opening |
| 3E0P7HZ | Introduction of Radioactive Substance into Female Reproductive, Via Natural or Artificial Opening |
| 3E0P7KZ | Introduction of Other Diagnostic Substance into Female Reproductive, Via Natural or Artificial Opening |
| 3E0P7LZ | Introduction of Sperm into Female Reproductive, Via Natural or Artificial Opening |
| 3E0P7NZ | Introduction of Analgesics, Hypnotics, Sedatives into Female Reproductive, Via Natural or Artificial Opening |
| 3E0P7Q0 | Introduction of Autologous Fertilized Ovum into Female Reproductive, Via Natural or Artificial Opening |
| 3E0P7Q1 | Introduction of Nonautologous Fertilized Ovum into Female Reproductive, Via Natural or Artificial Opening |
| 3E0P7SF | Introduction of Other Gas into Female Reproductive, Via Natural or Artificial Opening |
| 3E0P7TZ | Introduction of Destructive Agent into Female Reproductive, Via Natural or Artificial Opening |
| 3E0P7VZ | Introduction of Hormone into Female Reproductive, Via Natural or Artificial Opening |
| 3E0P804 | Introduction of Liquid Brachytherapy Radioisotope into Female Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0P805 | Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0P80M | Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0P828 | Introduction of Oxazolidinones into Female Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0P829 | Introduction of Other Anti-infective into Female Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0P83Z | Introduction of Anti-inflammatory into Female Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0P86Z | Introduction of Nutritional Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0P87Z | Introduction of Electrolytic and Water Balance Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0P8BZ | Introduction of Anesthetic Agent into Female Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0P8GC | Introduction of Other Therapeutic Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0P8HZ | Introduction of Radioactive Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0P8KZ | Introduction of Other Diagnostic Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0P8NZ | Introduction of Analgesics, Hypnotics, Sedatives into Female Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0P8SF | Introduction of Other Gas into Female Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0P8TZ | Introduction of Destructive Agent into Female Reproductive, Via Natural or Artificial Opening Endoscopic |
| 3E0Q004 | Introduction of Liquid Brachytherapy Radioisotope into Cranial Cavity and Brain, Open Approach |
| 3E0Q005 | Introduction of Other Antineoplastic into Cranial Cavity and Brain, Open Approach |
| 3E0Q00M | Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Open Approach |
| 3E0Q028 | Introduction of Oxazolidinones into Cranial Cavity and Brain, Open Approach |
| 3E0Q029 | Introduction of Other Anti-infective into Cranial Cavity and Brain, Open Approach |
| 3E0Q03Z | Introduction of Anti-inflammatory into Cranial Cavity and Brain, Open Approach |
| 3E0Q06Z | Introduction of Nutritional Substance into Cranial Cavity and Brain, Open Approach |
| 3E0Q07Z | Introduction of Electrolytic and Water Balance Substance into Cranial Cavity and Brain, Open Approach |
| 3E0Q0AZ | Introduction of Embryonic Stem Cells into Cranial Cavity and Brain, Open Approach |
| 3E0Q0BZ | Introduction of Anesthetic Agent into Cranial Cavity and Brain, Open Approach |
| 3E0Q0E0 | Introduction of Autologous Somatic Stem Cells into Cranial Cavity and Brain, Open Approach |
| 3E0Q0E1 | Introduction of Nonautologous Somatic Stem Cells into Cranial Cavity and Brain, Open Approach |
| 3E0Q0GC | Introduction of Other Therapeutic Substance into Cranial Cavity and Brain, Open Approach |
| 3E0Q0HZ | Introduction of Radioactive Substance into Cranial Cavity and Brain, Open Approach |
| 3E0Q0KZ | Introduction of Other Diagnostic Substance into Cranial Cavity and Brain, Open Approach |
| 3E0Q0NZ | Introduction of Analgesics, Hypnotics, Sedatives into Cranial Cavity and Brain, Open Approach |
| 3E0Q0SF | Introduction of Other Gas into Cranial Cavity and Brain, Open Approach |
| 3E0Q0TZ | Introduction of Destructive Agent into Cranial Cavity and Brain, Open Approach |
| 3E0Q304 | Introduction of Liquid Brachytherapy Radioisotope into Cranial Cavity and Brain, Percutaneous Approach |
| 3E0Q305 | Introduction of Other Antineoplastic into Cranial Cavity and Brain, Percutaneous Approach |
| 3E0Q30M | Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Percutaneous Approach |
| 3E0Q328 | Introduction of Oxazolidinones into Cranial Cavity and Brain, Percutaneous Approach |
| 3E0Q329 | Introduction of Other Anti-infective into Cranial Cavity and Brain, Percutaneous Approach |
| 3E0Q33Z | Introduction of Anti-inflammatory into Cranial Cavity and Brain, Percutaneous Approach |
| 3E0Q36Z | Introduction of Nutritional Substance into Cranial Cavity and Brain, Percutaneous Approach |
| 3E0Q37Z | Introduction of Electrolytic and Water Balance Substance into Cranial Cavity and Brain, Percutaneous Approach |
| 3E0Q3AZ | Introduction of Embryonic Stem Cells into Cranial Cavity and Brain, Percutaneous Approach |
| 3E0Q3BZ | Introduction of Anesthetic Agent into Cranial Cavity and Brain, Percutaneous Approach |
| 3E0Q3E0 | Introduction of Autologous Somatic Stem Cells into Cranial Cavity and Brain, Percutaneous Approach |
| 3E0Q3E1 | Introduction of Nonautologous Somatic Stem Cells into Cranial Cavity and Brain, Percutaneous Approach |
| 3E0Q3GC | Introduction of Other Therapeutic Substance into Cranial Cavity and Brain, Percutaneous Approach |
| 3E0Q3HZ | Introduction of Radioactive Substance into Cranial Cavity and Brain, Percutaneous Approach |
| 3E0Q3KZ | Introduction of Other Diagnostic Substance into Cranial Cavity and Brain, Percutaneous Approach |
| 3E0Q3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Cranial Cavity and Brain, Percutaneous Approach |
| 3E0Q3SF | Introduction of Other Gas into Cranial Cavity and Brain, Percutaneous Approach |
| 3E0Q3TZ | Introduction of Destructive Agent into Cranial Cavity and Brain, Percutaneous Approach |
| 3E0Q704 | Introduction of Liquid Brachytherapy Radioisotope into Cranial Cavity and Brain, Via Natural or Artificial Opening |
| 3E0Q705 | Introduction of Other Antineoplastic into Cranial Cavity and Brain, Via Natural or Artificial Opening |
| 3E0Q70M | Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Via Natural or Artificial Opening |
| 3E0Q7SF | Introduction of Other Gas into Cranial Cavity and Brain, Via Natural or Artificial Opening |
| 3E0R0AZ | Introduction of Embryonic Stem Cells into Spinal Canal, Open Approach |
| 3E0R0E0 | Introduction of Autologous Somatic Stem Cells into Spinal Canal, Open Approach |
| 3E0R0E1 | Introduction of Nonautologous Somatic Stem Cells into Spinal Canal, Open Approach |
| 3E0R302 | Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach |
| 3E0R303 | Introduction of Low-dose Interleukin-2 into Spinal Canal, Percutaneous Approach |
| 3E0R304 | Introduction of Liquid Brachytherapy Radioisotope into Spinal Canal, Percutaneous Approach |
| 3E0R305 | Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach |
| 3E0R30M | Introduction of Antineoplastic, Monoclonal Antibody, into Spinal Canal, Percutaneous Approach |
| 3E0R328 | Introduction of Oxazolidinones into Spinal Canal, Percutaneous Approach |
| 3E0R329 | Introduction of Other Anti-infective into Spinal Canal, Percutaneous Approach |
| 3E0R33Z | Introduction of Anti-inflammatory into Spinal Canal, Percutaneous Approach |
| 3E0R36Z | Introduction of Nutritional Substance into Spinal Canal, Percutaneous Approach |
| 3E0R37Z | Introduction of Electrolytic and Water Balance Substance into Spinal Canal, Percutaneous Approach |
| 3E0R3AZ | Introduction of Embryonic Stem Cells into Spinal Canal, Percutaneous Approach |
| 3E0R3BZ | Introduction of Anesthetic Agent into Spinal Canal, Percutaneous Approach |
| 3E0R3E0 | Introduction of Autologous Somatic Stem Cells into Spinal Canal, Percutaneous Approach |
| 3E0R3E1 | Introduction of Nonautologous Somatic Stem Cells into Spinal Canal, Percutaneous Approach |
| 3E0R3GC | Introduction of Other Therapeutic Substance into Spinal Canal, Percutaneous Approach |
| 3E0R3HZ | Introduction of Radioactive Substance into Spinal Canal, Percutaneous Approach |
| 3E0R3KZ | Introduction of Other Diagnostic Substance into Spinal Canal, Percutaneous Approach |
| 3E0R3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Spinal Canal, Percutaneous Approach |
| 3E0R3SF | Introduction of Other Gas into Spinal Canal, Percutaneous Approach |
| 3E0R3TZ | Introduction of Destructive Agent into Spinal Canal, Percutaneous Approach |
| 3E0R7SF | Introduction of Other Gas into Spinal Canal, Via Natural or Artificial Opening |
| 3E0S302 | Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach |
| 3E0S303 | Introduction of Low-dose Interleukin-2 into Epidural Space, Percutaneous Approach |
| 3E0S304 | Introduction of Liquid Brachytherapy Radioisotope into Epidural Space, Percutaneous Approach |
| 3E0S305 | Introduction of Other Antineoplastic into Epidural Space, Percutaneous Approach |
| 3E0S30M | Introduction of Antineoplastic, Monoclonal Antibody, into Epidural Space, Percutaneous Approach |
| 3E0S328 | Introduction of Oxazolidinones into Epidural Space, Percutaneous Approach |
| 3E0S329 | Introduction of Other Anti-infective into Epidural Space, Percutaneous Approach |
| 3E0S33Z | Introduction of Anti-inflammatory into Epidural Space, Percutaneous Approach |
| 3E0S36Z | Introduction of Nutritional Substance into Epidural Space, Percutaneous Approach |
| 3E0S37Z | Introduction of Electrolytic and Water Balance Substance into Epidural Space, Percutaneous Approach |
| 3E0S3BZ | Introduction of Anesthetic Agent into Epidural Space, Percutaneous Approach |
| 3E0S3GC | Introduction of Other Therapeutic Substance into Epidural Space, Percutaneous Approach |
| 3E0S3HZ | Introduction of Radioactive Substance into Epidural Space, Percutaneous Approach |
| 3E0S3KZ | Introduction of Other Diagnostic Substance into Epidural Space, Percutaneous Approach |
| 3E0S3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Epidural Space, Percutaneous Approach |
| 3E0S3SF | Introduction of Other Gas into Epidural Space, Percutaneous Approach |
| 3E0S3TZ | Introduction of Destructive Agent into Epidural Space, Percutaneous Approach |
| 3E0S7SF | Introduction of Other Gas into Epidural Space, Via Natural or Artificial Opening |
| 3E0T33Z | Introduction of Anti-inflammatory into Peripheral Nerves and Plexi, Percutaneous Approach |
| 3E0T3BZ | Introduction of Anesthetic Agent into Peripheral Nerves and Plexi, Percutaneous Approach |
| 3E0T3GC | Introduction of Other Therapeutic Substance into Peripheral Nerves and Plexi, Percutaneous Approach |
| 3E0T3TZ | Introduction of Destructive Agent into Peripheral Nerves and Plexi, Percutaneous Approach |
| 3E0U028 | Introduction of Oxazolidinones into Joints, Open Approach |
| 3E0U029 | Introduction of Other Anti-infective into Joints, Open Approach |
| 3E0U0GB | Introduction of Recombinant Bone Morphogenetic Protein into Joints, Open Approach |
| 3E0U304 | Introduction of Liquid Brachytherapy Radioisotope into Joints, Percutaneous Approach |
| 3E0U305 | Introduction of Other Antineoplastic into Joints, Percutaneous Approach |
| 3E0U30M | Introduction of Antineoplastic, Monoclonal Antibody, into Joints, Percutaneous Approach |
| 3E0U328 | Introduction of Oxazolidinones into Joints, Percutaneous Approach |
| 3E0U329 | Introduction of Other Anti-infective into Joints, Percutaneous Approach |
| 3E0U33Z | Introduction of Anti-inflammatory into Joints, Percutaneous Approach |
| 3E0U36Z | Introduction of Nutritional Substance into Joints, Percutaneous Approach |
| 3E0U37Z | Introduction of Electrolytic and Water Balance Substance into Joints, Percutaneous Approach |
| 3E0U3BZ | Introduction of Anesthetic Agent into Joints, Percutaneous Approach |
| 3E0U3GB | Introduction of Recombinant Bone Morphogenetic Protein into Joints, Percutaneous Approach |
| 3E0U3GC | Introduction of Other Therapeutic Substance into Joints, Percutaneous Approach |
| 3E0U3HZ | Introduction of Radioactive Substance into Joints, Percutaneous Approach |
| 3E0U3KZ | Introduction of Other Diagnostic Substance into Joints, Percutaneous Approach |
| 3E0U3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Joints, Percutaneous Approach |
| 3E0U3SF | Introduction of Other Gas into Joints, Percutaneous Approach |
| 3E0U3TZ | Introduction of Destructive Agent into Joints, Percutaneous Approach |
| 3E0U4GC | Introduction of Other Therapeutic Substance into Joints, Percutaneous Endoscopic Approach |
| 3E0V0GB | Introduction of Recombinant Bone Morphogenetic Protein into Bones, Open Approach |
| 3E0V0GC | Introduction of Other Therapeutic Substance into Bones, Open Approach |
| 3E0V305 | Introduction of Other Antineoplastic into Bones, Percutaneous Approach |
| 3E0V30M | Introduction of Antineoplastic, Monoclonal Antibody, into Bones, Percutaneous Approach |
| 3E0V328 | Introduction of Oxazolidinones into Bones, Percutaneous Approach |
| 3E0V329 | Introduction of Other Anti-infective into Bones, Percutaneous Approach |
| 3E0V33Z | Introduction of Anti-inflammatory into Bones, Percutaneous Approach |
| 3E0V36Z | Introduction of Nutritional Substance into Bones, Percutaneous Approach |
| 3E0V37Z | Introduction of Electrolytic and Water Balance Substance into Bones, Percutaneous Approach |
| 3E0V3BZ | Introduction of Anesthetic Agent into Bones, Percutaneous Approach |
| 3E0V3GB | Introduction of Recombinant Bone Morphogenetic Protein into Bones, Percutaneous Approach |
| 3E0V3GC | Introduction of Other Therapeutic Substance into Bones, Percutaneous Approach |
| 3E0V3HZ | Introduction of Radioactive Substance into Bones, Percutaneous Approach |
| 3E0V3KZ | Introduction of Other Diagnostic Substance into Bones, Percutaneous Approach |
| 3E0V3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Bones, Percutaneous Approach |
| 3E0V3TZ | Introduction of Destructive Agent into Bones, Percutaneous Approach |
| 3E0V4GC | Introduction of Other Therapeutic Substance into Bones, Percutaneous Endoscopic Approach |
| 3E0W305 | Introduction of Other Antineoplastic into Lymphatics, Percutaneous Approach |
| 3E0W30M | Introduction of Antineoplastic, Monoclonal Antibody, into Lymphatics, Percutaneous Approach |
| 3E0W328 | Introduction of Oxazolidinones into Lymphatics, Percutaneous Approach |
| 3E0W329 | Introduction of Other Anti-infective into Lymphatics, Percutaneous Approach |
| 3E0W33Z | Introduction of Anti-inflammatory into Lymphatics, Percutaneous Approach |
| 3E0W36Z | Introduction of Nutritional Substance into Lymphatics, Percutaneous Approach |
| 3E0W37Z | Introduction of Electrolytic and Water Balance Substance into Lymphatics, Percutaneous Approach |
| 3E0W3BZ | Introduction of Anesthetic Agent into Lymphatics, Percutaneous Approach |
| 3E0W3GC | Introduction of Other Therapeutic Substance into Lymphatics, Percutaneous Approach |
| 3E0W3HZ | Introduction of Radioactive Substance into Lymphatics, Percutaneous Approach |
| 3E0W3KZ | Introduction of Other Diagnostic Substance into Lymphatics, Percutaneous Approach |
| 3E0W3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Lymphatics, Percutaneous Approach |
| 3E0W3TZ | Introduction of Destructive Agent into Lymphatics, Percutaneous Approach |
| 3E0X33Z | Introduction of Anti-inflammatory into Cranial Nerves, Percutaneous Approach |
| 3E0X3BZ | Introduction of Anesthetic Agent into Cranial Nerves, Percutaneous Approach |
| 3E0X3GC | Introduction of Other Therapeutic Substance into Cranial Nerves, Percutaneous Approach |
| 3E0X3TZ | Introduction of Destructive Agent into Cranial Nerves, Percutaneous Approach |
| 3E0Y304 | Introduction of Liquid Brachytherapy Radioisotope into Pericardial Cavity, Percutaneous Approach |
| 3E0Y305 | Introduction of Other Antineoplastic into Pericardial Cavity, Percutaneous Approach |
| 3E0Y30M | Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Percutaneous Approach |
| 3E0Y328 | Introduction of Oxazolidinones into Pericardial Cavity, Percutaneous Approach |
| 3E0Y329 | Introduction of Other Anti-infective into Pericardial Cavity, Percutaneous Approach |
| 3E0Y33Z | Introduction of Anti-inflammatory into Pericardial Cavity, Percutaneous Approach |
| 3E0Y36Z | Introduction of Nutritional Substance into Pericardial Cavity, Percutaneous Approach |
| 3E0Y37Z | Introduction of Electrolytic and Water Balance Substance into Pericardial Cavity, Percutaneous Approach |
| 3E0Y3BZ | Introduction of Anesthetic Agent into Pericardial Cavity, Percutaneous Approach |
| 3E0Y3GC | Introduction of Other Therapeutic Substance into Pericardial Cavity, Percutaneous Approach |
| 3E0Y3HZ | Introduction of Radioactive Substance into Pericardial Cavity, Percutaneous Approach |
| 3E0Y3KZ | Introduction of Other Diagnostic Substance into Pericardial Cavity, Percutaneous Approach |
| 3E0Y3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Pericardial Cavity, Percutaneous Approach |
| 3E0Y3SF | Introduction of Other Gas into Pericardial Cavity, Percutaneous Approach |
| 3E0Y3TZ | Introduction of Destructive Agent into Pericardial Cavity, Percutaneous Approach |
| 3E0Y4GC | Introduction of Other Therapeutic Substance into Pericardial Cavity, Percutaneous Endoscopic Approach |
| 3E0Y704 | Introduction of Liquid Brachytherapy Radioisotope into Pericardial Cavity, Via Natural or Artificial Opening |
| 3E0Y705 | Introduction of Other Antineoplastic into Pericardial Cavity, Via Natural or Artificial Opening |
| 3E0Y70M | Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Via Natural or Artificial Opening |
| 3E0Y7SF | Introduction of Other Gas into Pericardial Cavity, Via Natural or Artificial Opening |